1
|
Delgado-Martín S, Martínez-Ruiz A. The role of ferroptosis as a regulator of oxidative stress in the pathogenesis of ischemic stroke. FEBS Lett 2024. [PMID: 38676284 DOI: 10.1002/1873-3468.14894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2023] [Revised: 03/25/2024] [Accepted: 04/02/2024] [Indexed: 04/28/2024]
Abstract
Ferroptosis is a unique form of cell death that was first described in 2012 and plays a significant role in various diseases, including neurodegenerative conditions. It depends on a dysregulation of cellular iron metabolism, which increases free, redox-active, iron that can trigger Fenton reactions, generating hydroxyl radicals that damage cells through oxidative stress and lipid peroxidation. Lipid peroxides, resulting mainly from unsaturated fatty acids, damage cells by disrupting membrane integrity and propagating cell death signals. Moreover, lipid peroxide degradation products can further affect cellular components such as DNA, proteins, and amines. In ischemic stroke, where blood flow to the brain is restricted, there is increased iron absorption, oxidative stress, and compromised blood-brain barrier integrity. Imbalances in iron-transport and -storage proteins increase lipid oxidation and contribute to neuronal damage, thus pointing to the possibility of brain cells, especially neurons, dying from ferroptosis. Here, we review the evidence showing a role of ferroptosis in ischemic stroke, both in recent studies directly assessing this type of cell death, as well as in previous studies showing evidence that can now be revisited with our new knowledge on ferroptosis mechanisms. We also review the efforts made to target ferroptosis in ischemic stroke as a possible treatment to mitigate cellular damage and death.
Collapse
Affiliation(s)
- Susana Delgado-Martín
- Unidad de Investigación, Hospital Santa Cristina, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain
| | - Antonio Martínez-Ruiz
- Unidad de Investigación, Hospital Santa Cristina, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain
- Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad Complutense de Madrid, Spain
| |
Collapse
|
2
|
Halliwell B. Understanding mechanisms of antioxidant action in health and disease. Nat Rev Mol Cell Biol 2024; 25:13-33. [PMID: 37714962 DOI: 10.1038/s41580-023-00645-4] [Citation(s) in RCA: 22] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/17/2023] [Indexed: 09/17/2023]
Abstract
Several different reactive oxygen species (ROS) are generated in vivo. They have roles in the development of certain human diseases whilst also performing physiological functions. ROS are counterbalanced by an antioxidant defence network, which functions to modulate ROS levels to allow their physiological roles whilst minimizing the oxidative damage they cause that can contribute to disease development. This Review describes the mechanisms of action of antioxidants synthesized in vivo, antioxidants derived from the human diet and synthetic antioxidants developed as therapeutic agents, with a focus on the gaps in our current knowledge and the approaches needed to close them. The Review also explores the reasons behind the successes and failures of antioxidants in treating or preventing human disease. Antioxidants may have special roles in the gastrointestinal tract, and many lifestyle features known to promote health (especially diet, exercise and the control of blood glucose and cholesterol levels) may be acting, at least in part, by antioxidant mechanisms. Certain reactive sulfur species may be important antioxidants but more accurate determinations of their concentrations in vivo are needed to help assess their contributions.
Collapse
Affiliation(s)
- Barry Halliwell
- Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- Neurobiology Research Programme, Life Sciences Institute, Centre for Life Sciences, National University of Singapore, Singapore, Singapore.
| |
Collapse
|
3
|
Tripodi D, Vitarelli F, Spiti S, Leoni V. The Diagnostic Use of the Plasma Quantification of 24S-Hydroxycholesterol and Other Oxysterols in Neurodegenerative Disease. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2024; 1440:337-351. [PMID: 38036888 DOI: 10.1007/978-3-031-43883-7_17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/02/2023]
Abstract
Cholesterol regulates fluidity and structure of cellular membranes. The brain is involved in signal transduction, synaptogenesis, and membrane trafficking. An impairment of its metabolism was observed in different neurodegenerative diseases, such as Multiple Sclerosis, Alzheimer, and Huntington diseases. Because of the blood-brain barrier, cholesterol cannot be uptaken from the circulation and all the cholesterol is locally synthetized. The excess cholesterol in neurons is converted into 24S-hydroxycholesterol (24OHC) by the cholesterol 24-hydroxylase (CYP46A1). The plasmatic concentration of 24OHC results in the balance between cerebral production and liver elimination. It is related to the number of metabolically active neurons in the brain. Several factors that affect the brain cholesterol turnover and the liver elimination of oxysterols, the genetic background, nutrition, and lifestyle habits were found to significantly affect plasma levels of 24OHC. Reduced levels of 24OHC were found related to the loss of metabolically active cells and the degree of brain atrophy. The dysfunction of the blood-brain barrier, inflammation, and increased cholesterol turnover might overlap with this progressive reduction giving temporary increased levels of 24OHC.The study of plasma 24OHC is likely to offer an insight into brain cholesterol turnover with a limited diagnostic power.
Collapse
Affiliation(s)
- Domenico Tripodi
- Laboratory of Clinical Pathology, Hospital Pio XI of Desio, ASST-Brianza and Department of Medicine and Surgery, University of Milano Bicocca, Desio, MB, Italy
| | - Federica Vitarelli
- Laboratory of Clinical Pathology, Hospital Pio XI of Desio, ASST-Brianza and Department of Medicine and Surgery, University of Milano Bicocca, Desio, MB, Italy
| | - Simona Spiti
- Laboratory of Clinical Pathology, Hospital Pio XI of Desio, ASST-Brianza and Department of Medicine and Surgery, University of Milano Bicocca, Desio, MB, Italy
| | - Valerio Leoni
- Laboratory of Clinical Pathology, Hospital Pio XI of Desio, ASST-Brianza and Department of Medicine and Surgery, University of Milano Bicocca, Desio, MB, Italy.
| |
Collapse
|
4
|
Fayyazi F, Ebrahimi V, Mamaghani MM, Abgharmi BA, Zarrini G, Mosarrezaii A, Charkhian H, Gholinejad Z. N-Acetyl cysteine amide and cerium oxide nanoparticles as a drug delivery for ischemic stroke treatment: Inflammation and oxidative stress crosstalk. J Trace Elem Med Biol 2023; 80:127300. [PMID: 37741051 DOI: 10.1016/j.jtemb.2023.127300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/26/2023] [Revised: 09/04/2023] [Accepted: 09/05/2023] [Indexed: 09/25/2023]
Abstract
BACKGROUND Inflammation and oxidative stress crosstalk is involved in the ischemic stroke(IS) pathogenesis and the new therapeutic options should be offered based on the targets that are critical in the golden hour of IS. YKL-40 and total antioxidant capacity(TAC), the inflammation and oxidative stress biomarkers, provide us with clues for proper intervention targets. N-acetyl cysteine amide (NACA), a lipophilic antioxidant, with a nanoparticle-based drug delivery system is permeable enough to penetrate blood-brain barrier (BBB) and was proposed as a new treatment option for IS. In this study, we evaluated the YKL-40 and TAC levels in the sera of IS patients to elucidate the best intervention target. A rat tissue model is used to assess the NACA efficiency. The microbiology tests performed to figure out the potential NACA and antibiotics interactions. MATERIAL AND METHODS The YKL-40 and TAC were measured in the serum of IS patients by ELISA and FRAP methods, respectively. The serum samples were obtained 12 h after the patient's admission and meantime other laboratory findings and NIHSS-based prognosis were recorded. In the animal study, the brain cortex, liver, kidney, adipose, and the heart of healthy rats were dissected and then incubated in DMEM cell culture media containing 50 micrograms/milliliter of nanoparticles; the nanoparticles were titanium dioxide nanoparticles (TiO2 NPs), copper oxide nanoparticles (CuO NPs) and cerium dioxide nanoparticles (CeO2 NPs). Olive oil and human serum albumin solution were exposed to the nanoparticles with and without NACA. TAC was measured in the supernatant culture media. With similar concentrations and settings, we evaluated the NACA, nanoparticle, and antibiotics interactions on pseudomonas aeruginosa. RESULTS There was a nonparametric correlation between YKL-40 levels and post stroke serum TAC levels. Nonsmokers had higher YKL-40 and TAC levels than smokers. A new calculated variable, urea*lymphocyte/age, predicts a poor prognosis with an acceptable AUC (0.708). Exposing to the nanoparticles, the liver, kidney, and brain had a significantly higher TAC than adipose and cardiac tissue. The NACA had an ameliorative effect against TiO2 NPs in the brain. This effectiveness of NACA was also observed against CuO NPs treatment. However, the CeO2 NPs exert a strong antioxidant property by reducing the TAC in the brain tissue but not the others. Albumin showed antioxidant properties by itself, but olive oil had an inert behavior. NACA had no interaction with the action of routine antibiotics. CONCLUSION Oxidative stress but not inflammation is the best point for intervention in IS patients because YKL-40 has not a relationship with NIHSS score. The CeO2 NPs and NACA combination are eligible option to develop antioxidant-based drug for the treatment of IS. As a complementary finding, the urea*lymphocyte/age is proposed as a NIHSS-based prognosis biomarker.
Collapse
Affiliation(s)
- Farzin Fayyazi
- Department of Neurology, Urmia University of Medical Sciences, Urmia, Iran
| | - Vahed Ebrahimi
- Department of Biochemistry, Science and Research Branch, Islamic Azad University, Tehran, Iran
| | | | - Benyamin Azad Abgharmi
- Department of Microbiology Science, Tabriz Branch, Islamic Azad University, Tabriz, Iran
| | - Gholamreza Zarrini
- Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran
| | - Arash Mosarrezaii
- Department of Neurology, Urmia University of Medical Sciences, Urmia, Iran.
| | - Hamed Charkhian
- Young Researchers and Elite Club, Islamic Azad University, Urmia Branch, Urmia, Iran
| | - Zafar Gholinejad
- Department of Medical Laboratory Science, Urmia Branch, Islamic Azad University, Urmia, Iran.
| |
Collapse
|
5
|
Kamal FZ, Lefter R, Jaber H, Balmus IM, Ciobica A, Iordache AC. The Role of Potential Oxidative Biomarkers in the Prognosis of Acute Ischemic Stroke and the Exploration of Antioxidants as Possible Preventive and Treatment Options. Int J Mol Sci 2023; 24:ijms24076389. [PMID: 37047362 PMCID: PMC10094154 DOI: 10.3390/ijms24076389] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Revised: 03/27/2023] [Accepted: 03/27/2023] [Indexed: 03/31/2023] Open
Abstract
Ischemic strokes occur when the blood supply to a part of the brain is interrupted or reduced due to arterial blockage, and it often leads to damage to brain cells or death. According to a myriad of experimental studies, oxidative stress is an important pathophysiological mechanism of ischemic stroke. In this narrative review, we aimed to identify how the alterations of oxidative stress biomarkers could suggest a severity-reflecting diagnosis of ischemic stroke and how these interactions may provide new molecular targets for neuroprotective therapies. We performed an eligibility criteria-based search on three main scientific databases. We found that patients with acute ischemic stroke are characterized by increased oxidative stress markers levels, such as the total antioxidant capacity, F2-isoprostanes, hydroxynonenal, total and perchloric acid oxygen radical absorbance capacity (ORACTOT and ORACPCA), malondialdehyde (MDA), myeloperoxidase, and urinary 8-oxo-7,8-dihydro-2′-deoxyguanosine. Thus, acute ischemic stroke is causing significant oxidative stress and associated molecular and cellular damage. The assessment of these molecular markers could be useful in diagnosing ischemic stroke, finding its causes, predicting its severity and outcomes, reducing its impact on the cellular structures of the brain, and guiding preventive treatment towards antioxidant-based therapy as novel therapeutic alternatives.
Collapse
|
6
|
Moretti E, Signorini C, Noto D, Corsaro R, Micheli L, Durand T, Oger C, Galano JM, Collodel G. F 4-Neuroprostane Effects on Human Sperm. Int J Mol Sci 2023; 24:ijms24020935. [PMID: 36674450 PMCID: PMC9861396 DOI: 10.3390/ijms24020935] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2022] [Revised: 12/20/2022] [Accepted: 12/20/2022] [Indexed: 01/06/2023] Open
Abstract
Swim-up selected human sperm were incubated with 7 ng F4-neuroprostanes (F4-NeuroPs) for 2 and 4 h. Sperm motility and membrane mitochondrial potential (MMP) were evaluated. The percentage of reacted acrosome was assessed by pisum sativum agglutinin (PSA). Chromatin integrity was detected using the acridine orange (AO) assay and localization of the ryanodine receptor was performed by immunofluorescence analysis. Sperm progressive motility (p = 0.02) and the percentage of sperm showing a strong MMP signal (p = 0.012) significantly increased after 2 h F4-NeuroP incubation compared to control samples. The AO assay did not show differences in the percentage of sperm with dsDNA between treated or control samples. Meanwhile, a significantly higher number of sperm with reacted acrosomes was highlighted by PSA localization after 4 h F4-NeuroP incubation. Finally, using an anti-ryanodine antibody, the immunofluorescence signal was differentially distributed at 2 and 4 h: a strong signal was evident in the midpiece and postacrosomal sheath (70% of sperm) at 2 h, whereas a dotted one appeared at 4 h (53% of sperm). A defined concentration of F4-NeuroPs in seminal fluid may induce sperm capacitation via channel ions present in sperm cells, representing an aid during in vitro sperm preparation that may increase the positive outcome of assisted fertilization.
Collapse
Affiliation(s)
- Elena Moretti
- Department of Molecular and Developmental Medicine, Policlinico Le Scotte, University of Siena, 53100 Siena, Italy
| | - Cinzia Signorini
- Department of Molecular and Developmental Medicine, Policlinico Le Scotte, University of Siena, 53100 Siena, Italy
- Correspondence:
| | - Daria Noto
- Department of Molecular and Developmental Medicine, Policlinico Le Scotte, University of Siena, 53100 Siena, Italy
| | - Roberta Corsaro
- Department of Molecular and Developmental Medicine, Policlinico Le Scotte, University of Siena, 53100 Siena, Italy
| | - Lucia Micheli
- Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy
| | - Thierry Durand
- Institut des Biomolécules Max Mousseron (IBMM), Pole Chimie Balard Recherche, UMR 5247, CNRS, Université de Montpellier, ENSCM, 34090 Montpellier, France
| | - Camille Oger
- Institut des Biomolécules Max Mousseron (IBMM), Pole Chimie Balard Recherche, UMR 5247, CNRS, Université de Montpellier, ENSCM, 34090 Montpellier, France
| | - Jean Marie Galano
- Institut des Biomolécules Max Mousseron (IBMM), Pole Chimie Balard Recherche, UMR 5247, CNRS, Université de Montpellier, ENSCM, 34090 Montpellier, France
| | - Giulia Collodel
- Department of Molecular and Developmental Medicine, Policlinico Le Scotte, University of Siena, 53100 Siena, Italy
| |
Collapse
|
7
|
Inflammageing and Cardiovascular System: Focus on Cardiokines and Cardiac-Specific Biomarkers. Int J Mol Sci 2023; 24:ijms24010844. [PMID: 36614282 PMCID: PMC9820990 DOI: 10.3390/ijms24010844] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2022] [Revised: 12/26/2022] [Accepted: 12/28/2022] [Indexed: 01/05/2023] Open
Abstract
The term "inflammageing" was introduced in 2000, with the aim of describing the chronic inflammatory state typical of elderly individuals, which is characterized by a combination of elevated levels of inflammatory biomarkers, a high burden of comorbidities, an elevated risk of disability, frailty, and premature death. Inflammageing is a hallmark of various cardiovascular diseases, including atherosclerosis, hypertension, and rapid progression to heart failure. The great experimental and clinical evidence accumulated in recent years has clearly demonstrated that early detection and counteraction of inflammageing is a promising strategy not only to prevent cardiovascular disease, but also to slow down the progressive decline of health that occurs with ageing. It is conceivable that beneficial effects of counteracting inflammageing should be most effective if implemented in the early stages, when the compensatory capacity of the organism is not completely exhausted. Early interventions and treatments require early diagnosis using reliable and cost-effective biomarkers. Indeed, recent clinical studies have demonstrated that cardiac-specific biomarkers (i.e., cardiac natriuretic peptides and cardiac troponins) are able to identify, even in the general population, the individuals at highest risk of progression to heart failure. However, further clinical studies are needed to better understand the usefulness and cost/benefit ratio of cardiac-specific biomarkers as potential targets in preventive and therapeutic strategies for early detection and counteraction of inflammageing mechanisms and in this way slowing the progressive decline of health that occurs with ageing.
Collapse
|
8
|
Kumar V, Bishayee K, Park S, Lee U, Kim J. Oxidative stress in cerebrovascular disease and associated diseases. Front Endocrinol (Lausanne) 2023; 14:1124419. [PMID: 36875474 PMCID: PMC9982100 DOI: 10.3389/fendo.2023.1124419] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/15/2022] [Accepted: 02/02/2023] [Indexed: 02/19/2023] Open
Abstract
Cellular aging is the most severe risk factor for neurodegenerative disease. Simultaneously, oxidative stress (OS) is a critical factor in the aging process, resulting from an imbalance between reactive oxygen and nitrogen species and the antioxidant defense system. Emerging evidence indicates that OS is a common cause of several age-related brain pathologies, including cerebrovascular diseases. Elevated OS disrupts endothelial functional ability by diminishing the bioavailability of nitric oxide (a vascular dilator), induces atherosclerosis, and impairs vasculature, which are all common characteristics of cerebrovascular disease. In this review, we summarize evidence supporting an active role of OS in cerebrovascular disease progression, focusing primarily on stroke pathogenesis. We briefly discuss hypertension, diabetes, heart disease, and genetic factors that are often linked to OS and are considered associated factors influencing stroke pathology. Finally, we discuss the current pharmaceutics/therapeutics available for treating several cerebrovascular diseases.
Collapse
Affiliation(s)
- Vijay Kumar
- Department of Biochemistry, Institute of Cell Differentiation and Aging, College of Medicine, Hallym University, Chuncheon, Republic of Korea
| | - Kausik Bishayee
- Biomedical Science Core-Facility, Soonchunhyang Institute of Medi-Bio Science, Soonchunhyang University, Cheonan, Republic of Korea
| | - Soochul Park
- Department of Biological Sciences, Sookmyung Women’s University, Seoul, Republic of Korea
| | - Unjoo Lee
- Department of Electrical Engineering, Hallym University, Chuncheon, Republic of Korea
| | - Jaebong Kim
- Department of Biochemistry, Institute of Cell Differentiation and Aging, College of Medicine, Hallym University, Chuncheon, Republic of Korea
- *Correspondence: Jaebong Kim,
| |
Collapse
|
9
|
Wang P, Cui Y, Liu Y, Li Z, Bai H, Zhao Y, Chang YZ. Mitochondrial ferritin alleviates apoptosis by enhancing mitochondrial bioenergetics and stimulating glucose metabolism in cerebral ischemia reperfusion. Redox Biol 2022; 57:102475. [PMID: 36179435 PMCID: PMC9526171 DOI: 10.1016/j.redox.2022.102475] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2022] [Accepted: 09/11/2022] [Indexed: 11/28/2022] Open
Abstract
Oxidative stress and deficient bioenergetics are key players in the pathological process of cerebral ischemia reperfusion injury (I/R). As a mitochondrial iron storage protein, mitochondrial ferritin (FtMt) plays a pivotal role in protecting neuronal cells from oxidative damage under stress conditions. However, the effects of FtMt in mitochondrial function and activation of apoptosis under cerebral I/R are barely understood. In the present study, we found that FtMt deficiency exacerbates neuronal apoptosis via classical mitochondria-depedent pathway and the endoplasmic reticulum (ER) stress pathway in brains exposed to I/R. Conversely, FtMt overexpression significantly inhibited oxygen and glucose deprivation and reperfusion (OGD/R)-induced apoptosis and the activation of ER stress response. Meanwhile, FtMt overexpression rescued OGD/R-induced mitochondrial iron overload, mitochondrial dysfunction, the generation of reactive oxygen species (ROS) and increased neuronal GSH content. Using the Seahorse and O2K cellular respiration analyser, we demonstrated that FtMt remarkably improved the ATP content and the spare respiratory capacity under I/R conditions. Importantly, we found that glucose consumption was augmented in FtMt overexpressing cells after OGD/R insult; overexpression of FtMt facilitated the activation of glucose 6-phosphate dehydrogenase and the production of NADPH in cells after OGD/R, indicating that the pentose-phosphate pathway is enhanced in FtMt overexpressing cells, thus strengthening the antioxidant capacity of neuronal cells. In summary, our results reveal that FtMt protects against I/R-induced apoptosis through enhancing mitochondrial bioenergetics and regulating glucose metabolism via the pentose-phosphate pathway, thus preventing ROS overproduction, and preserving energy metabolism.
Collapse
Affiliation(s)
- Peina Wang
- Laboratory of Molecular Iron Metabolism, Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology of Hebei Province, College of Life Science, Hebei Normal University, Shijiazhuang, 050024, Hebei Province, China; College of Basic Medicine, Hebei Medical University, Shijiazhuang, 050017, Hebei Province, China
| | - Yanmei Cui
- Laboratory of Molecular Iron Metabolism, Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology of Hebei Province, College of Life Science, Hebei Normal University, Shijiazhuang, 050024, Hebei Province, China
| | - Yuanyuan Liu
- Laboratory of Molecular Iron Metabolism, Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology of Hebei Province, College of Life Science, Hebei Normal University, Shijiazhuang, 050024, Hebei Province, China
| | - Zhongda Li
- Laboratory of Molecular Iron Metabolism, Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology of Hebei Province, College of Life Science, Hebei Normal University, Shijiazhuang, 050024, Hebei Province, China
| | - Huiyuan Bai
- Laboratory of Molecular Iron Metabolism, Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology of Hebei Province, College of Life Science, Hebei Normal University, Shijiazhuang, 050024, Hebei Province, China
| | - Yashuo Zhao
- Laboratory of Molecular Iron Metabolism, Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology of Hebei Province, College of Life Science, Hebei Normal University, Shijiazhuang, 050024, Hebei Province, China; Scientific Research Center, Hebei University of Chinese Medicine, Shijiazhuang, 050200, Hebei Province, China
| | - Yan-Zhong Chang
- Laboratory of Molecular Iron Metabolism, Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology of Hebei Province, College of Life Science, Hebei Normal University, Shijiazhuang, 050024, Hebei Province, China.
| |
Collapse
|
10
|
Halliwell B. Reflections of an Aging Free Radical Part 2: Meeting Inspirational People. Antioxid Redox Signal 2022; 38:792-802. [PMID: 35651275 DOI: 10.1089/ars.2022.0070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Significance: During my long career in the field of redox biology, I met many inspiring people, especially Lester Packer. Recent Advances: This special issue of Antioxidants & Redox Signaling is dedicated to Lester Packer. Critical Issues: In this short review, I explore how Lester and other pioneers helped to develop the redox biology field and how I interacted with them. Future Directions: In our research to advance the field of redox biology, we stand on the shoulders of giants, including Lester Packer.
Collapse
Affiliation(s)
- Barry Halliwell
- Department of Biochemistry, Yong Loo Lin School of Medicine, National University Singapore, Singapore, Singapore
| |
Collapse
|
11
|
Sutkowy P, Wróblewska J, Wróblewski M, Nuszkiewicz J, Modrzejewska M, Woźniak A. The Impact of Exercise on Redox Equilibrium in Cardiovascular Diseases. J Clin Med 2022; 11:jcm11164833. [PMID: 36013072 PMCID: PMC9410476 DOI: 10.3390/jcm11164833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2022] [Revised: 08/05/2022] [Accepted: 08/16/2022] [Indexed: 11/16/2022] Open
Abstract
Cardiovascular diseases constitute the most important public health problem in the world. They are characterized by inflammation and oxidative stress in the heart and blood. Physical activity is recognized as one of the best ways to prevent these diseases, and it has already been applied in treatment. Physical exercise, both aerobic and anaerobic and single and multiple, is linked to the oxidant–antioxidant imbalance; however, this leads to positive adaptive changes in, among others, the increase in antioxidant capacity. The goal of the paper was to discuss the issue of redox equilibrium in the human organism in the course of cardiovascular diseases to systemize updated knowledge in the context of exercise impacts on the organism. Antioxidant supplementation is also an important issue since antioxidant supplements still have great potential regarding their use as drugs in these diseases.
Collapse
|
12
|
Rotariu D, Babes EE, Tit DM, Moisi M, Bustea C, Stoicescu M, Radu AF, Vesa CM, Behl T, Bungau AF, Bungau SG. Oxidative stress - Complex pathological issues concerning the hallmark of cardiovascular and metabolic disorders. Biomed Pharmacother 2022; 152:113238. [PMID: 35687909 DOI: 10.1016/j.biopha.2022.113238] [Citation(s) in RCA: 56] [Impact Index Per Article: 28.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2022] [Revised: 05/30/2022] [Accepted: 06/02/2022] [Indexed: 12/07/2022] Open
Abstract
Oxidative stress is a complex biological process characterized by the excessive production of reactive oxygen species (ROS) that act as destroyers of the REDOX balance in the body and, implicitly, inducing oxidative damage. All the metabolisms are impaired in oxidative stress and even nucleic acid balance is influenced. ROS will promote structural changes of the tissues and organs due to interaction with proteins and phospholipids. The constellation of the cardiovascular risk factors (CVRFs) will usually develop in subjects with predisposition to cardiac disorders. Oxidative stress is usually related with hypertension (HTN), diabetes mellitus (DM), obesity and cardiovascular diseases (CVDs) like coronary artery disease (CAD), cardiomyopathy or heart failure (HF), that can develop in subjects with the above-mentioned diseases. Elements describing the complex relationship between CVD and oxidative stress should be properly explored and described because prevention may be the optimal approach. Our paper aims to expose in detail the complex physiopathology of oxidative stress in CVD occurrence and novelties regarding the phenomenon. Biomarkers assessing oxidative stress or therapy targeting specific pathways represent a major progress that actually change the outcome of subjects with CVD. New antioxidants therapy specific for each CVD represents a captivating and interesting future perspective with tremendous benefits on subject's outcome.
Collapse
Affiliation(s)
- Dragos Rotariu
- Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410087 Oradea, Romania.
| | - Emilia Elena Babes
- Department of Medical Disciplines, Faculty of Medicine and Pharmacy of Oradea, University of Oradea, 410073 Oradea, Romania.
| | - Delia Mirela Tit
- Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410087 Oradea, Romania; Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania.
| | - Madalina Moisi
- Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy of Oradea, University of Oradea, 410073 Oradea, Romania.
| | - Cristiana Bustea
- Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy of Oradea, University of Oradea, 410073 Oradea, Romania.
| | - Manuela Stoicescu
- Department of Medical Disciplines, Faculty of Medicine and Pharmacy of Oradea, University of Oradea, 410073 Oradea, Romania.
| | - Andrei-Flavius Radu
- Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410087 Oradea, Romania; Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy of Oradea, University of Oradea, 410073 Oradea, Romania.
| | - Cosmin Mihai Vesa
- Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy of Oradea, University of Oradea, 410073 Oradea, Romania.
| | - Tapan Behl
- Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India.
| | | | - Simona Gabriela Bungau
- Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410087 Oradea, Romania; Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania.
| |
Collapse
|
13
|
Urinary metabolites of type 2 diabetes rats fed with palm oil-enriched high fat diet. Heliyon 2021; 7:e08075. [PMID: 34632142 PMCID: PMC8487023 DOI: 10.1016/j.heliyon.2021.e08075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Revised: 08/17/2021] [Accepted: 09/23/2021] [Indexed: 11/25/2022] Open
Abstract
High fat diet (HFD) is one of the risk factors of obesity and diabetes. Recommended diet regimen for diabetes is difficult to abide by especially for HFD as it adds flavour to the taste buds. In this study, palm oil-enriched HFD and normal diet were fed to nicotinamide-induced type 2 diabetes rats, respectively for six weeks. Additionally, metformin, a common drug used to treat diabetes was given to rats under treatment groups. We evaluated the change of urinary metabolites of diabetes rats fed with palm oil-enriched HFD, and also after metformin treatment. Rats were divided into six-groups with different feeding diets, disease condition and with or without metformin treatment. Rats’ urine were collected at the end of six weeks feeding program and subjected to 1H-NMR and multivariate data analysis to evaluate their metabolite profiles. At the early phase of diabetes, metabolites changes in diabetic rats were associated with the disease itself. Our data showed that continuous consumption of HFD altered various metabolic pathways of diabetic rats and caused detrimental effects to the rats. On the other hand, metformin treatment combined with normal diet lessened the physiological impacts caused by diabetes condition.
Collapse
|
14
|
Yuan Q, Xin L, Han S, Su Y, Wu R, Liu X, Wuri J, Li R, Yan T. Lactulose Improves Neurological Outcomes by Repressing Harmful Bacteria and Regulating Inflammatory Reactions in Mice After Stroke. Front Cell Infect Microbiol 2021; 11:644448. [PMID: 34327147 PMCID: PMC8313872 DOI: 10.3389/fcimb.2021.644448] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2020] [Accepted: 06/28/2021] [Indexed: 12/16/2022] Open
Abstract
Background and Objective Gut microbiota dysbiosis following stroke affects the recovery of neurological function. Administration of prebiotics to counteract post-stroke dysbiosis may be a potential therapeutic strategy to improve neurological function. We aim to observe the effect of lactulose on neurological function outcomes, gut microbiota composition, and plasma metabolites in mice after stroke. Methods Male C57BL/6 mice (20–25 g) were randomly divided into three groups: healthy control, photothrombotic stroke + triple-distilled water, and photothrombotic stroke + lactulose. After 14 consecutive days of lactulose administration, feces, plasma, and organs were collected. 16S rDNA sequencing, plasma untargeted metabolomics, qPCR, flow cytometry and Elisa were performed. Results Lactulose supplementation significantly improved the functional outcome of stroke, downregulated inflammatory reaction, and increased anti-inflammatory factors in both the brain and gut. In addition, lactulose supplementation repaired intestinal barrier injury, improved gut microbiota dysbiosis, and partially amended metabolic disorder after stroke. Conclusion Lactulose promotes functional outcomes after stroke in mice, which may be attributable to repressing harmful bacteria, and metabolic disorder, repairing gut barrier disruption, and reducing inflammatory reactions after stroke.
Collapse
Affiliation(s)
- Quan Yuan
- Department of Neurology, Tianjin Medical University General Hospital, Tianjin Neurological Institute, Key Laboratory of Post-Neurotrauma, Neurorepair, and Regeneration in Central Nervous System, Ministry of Education and Tianjin City, Tianjin, China
| | - Ling Xin
- Department of Neurology, Tianjin Medical University General Hospital, Tianjin Neurological Institute, Key Laboratory of Post-Neurotrauma, Neurorepair, and Regeneration in Central Nervous System, Ministry of Education and Tianjin City, Tianjin, China
| | - Song Han
- Department of Neurology, Tianjin Medical University General Hospital, Tianjin Neurological Institute, Key Laboratory of Post-Neurotrauma, Neurorepair, and Regeneration in Central Nervous System, Ministry of Education and Tianjin City, Tianjin, China
| | - Yue Su
- Department of Neurology, Tianjin Medical University General Hospital, Tianjin Neurological Institute, Key Laboratory of Post-Neurotrauma, Neurorepair, and Regeneration in Central Nervous System, Ministry of Education and Tianjin City, Tianjin, China
| | - Ruixia Wu
- Department of Neurology, Tianjin Medical University General Hospital, Tianjin Neurological Institute, Key Laboratory of Post-Neurotrauma, Neurorepair, and Regeneration in Central Nervous System, Ministry of Education and Tianjin City, Tianjin, China
| | - Xiaoxuan Liu
- Department of Neurology, Tianjin Medical University General Hospital, Tianjin Neurological Institute, Key Laboratory of Post-Neurotrauma, Neurorepair, and Regeneration in Central Nervous System, Ministry of Education and Tianjin City, Tianjin, China
| | - Jimusi Wuri
- Department of Neurology, Tianjin Medical University General Hospital, Tianjin Neurological Institute, Key Laboratory of Post-Neurotrauma, Neurorepair, and Regeneration in Central Nervous System, Ministry of Education and Tianjin City, Tianjin, China
| | - Ran Li
- Department of Neurology, Tianjin Medical University General Hospital, Tianjin Neurological Institute, Key Laboratory of Post-Neurotrauma, Neurorepair, and Regeneration in Central Nervous System, Ministry of Education and Tianjin City, Tianjin, China
| | - Tao Yan
- Department of Neurology, Tianjin Medical University General Hospital, Tianjin Neurological Institute, Key Laboratory of Post-Neurotrauma, Neurorepair, and Regeneration in Central Nervous System, Ministry of Education and Tianjin City, Tianjin, China
| |
Collapse
|
15
|
Kulkarni A, Nadler JL, Mirmira RG, Casimiro I. Regulation of Tissue Inflammation by 12-Lipoxygenases. Biomolecules 2021; 11:717. [PMID: 34064822 PMCID: PMC8150372 DOI: 10.3390/biom11050717] [Citation(s) in RCA: 38] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Revised: 05/03/2021] [Accepted: 05/07/2021] [Indexed: 02/07/2023] Open
Abstract
Lipoxygenases (LOXs) are lipid metabolizing enzymes that catalyze the di-oxygenation of polyunsaturated fatty acids to generate active eicosanoid products. 12-lipoxygenases (12-LOXs) primarily oxygenate the 12th carbon of its substrates. Many studies have demonstrated that 12-LOXs and their eicosanoid metabolite 12-hydroxyeicosatetraenoate (12-HETE), have significant pathological implications in inflammatory diseases. Increased level of 12-LOX activity promotes stress (both oxidative and endoplasmic reticulum)-mediated inflammation, leading to damage in these tissues. 12-LOXs are also associated with enhanced cellular migration of immune cells-a characteristic of several metabolic and autoimmune disorders. Genetic depletion or pharmacological inhibition of the enzyme in animal models of various diseases has shown to be protective against disease development and/or progression in animal models in the setting of diabetes, pulmonary, cardiovascular, and metabolic disease, suggesting a translational potential of targeting the enzyme for the treatment of several disorders. In this article, we review the role of 12-LOXs in the pathogenesis of several diseases in which chronic inflammation plays an underlying role.
Collapse
Affiliation(s)
- Abhishek Kulkarni
- Department of Medicine, The University of Chicago, Chicago, IL 60637, USA;
| | - Jerry L. Nadler
- Department of Medicine and Pharmacology, New York Medical College, Valhalla, NY 10595, USA;
| | | | - Isabel Casimiro
- Department of Medicine, The University of Chicago, Chicago, IL 60637, USA;
| |
Collapse
|
16
|
Forman HJ, Zhang H. Targeting oxidative stress in disease: promise and limitations of antioxidant therapy. Nat Rev Drug Discov 2021; 20:689-709. [PMID: 34194012 PMCID: PMC8243062 DOI: 10.1038/s41573-021-00233-1] [Citation(s) in RCA: 847] [Impact Index Per Article: 282.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/12/2021] [Indexed: 02/06/2023]
Abstract
Oxidative stress is a component of many diseases, including atherosclerosis, chronic obstructive pulmonary disease, Alzheimer disease and cancer. Although numerous small molecules evaluated as antioxidants have exhibited therapeutic potential in preclinical studies, clinical trial results have been disappointing. A greater understanding of the mechanisms through which antioxidants act and where and when they are effective may provide a rational approach that leads to greater pharmacological success. Here, we review the relationships between oxidative stress, redox signalling and disease, the mechanisms through which oxidative stress can contribute to pathology, how antioxidant defences work, what limits their effectiveness and how antioxidant defences can be increased through physiological signalling, dietary components and potential pharmaceutical intervention.
Collapse
Affiliation(s)
- Henry Jay Forman
- University of California Merced, Merced, CA, USA. .,Leonard Davis School of Gerontology, University of Southern California, Los Angeles, CA, USA.
| | - Hongqiao Zhang
- grid.42505.360000 0001 2156 6853Leonard Davis School of Gerontology, University of Southern California, Los Angeles, CA USA
| |
Collapse
|
17
|
Abstract
In this mini-reflection, I explain how during my doctoral work in a Botany Department I first became interested in H2O2 and later in my career in other reactive oxygen species, especially the role of "catalytic" iron and haem compounds (including leghaemoglobin) in promoting oxidative damage. The important roles that H2O2, other ROS and dietary plants play in respect to humans are discussed. I also review the roles of diet-derived antioxidants in relation to human disease, presenting reasons why clinical trials using high doses of natural antioxidants have generally given disappointing results. Iron chelators and ergothioneine are reviewed as potential cytoprotective agents with antioxidant properties that may be useful therapeutically. The discovery of ferroptosis may also lead to novel agents that can be used to treat certain diseases.
Collapse
Affiliation(s)
- Barry Halliwell
- Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Centre for Life Sciences, #05-01A, 28 Medical Drive, 117456, Singapore.
| |
Collapse
|
18
|
Harpaz D, Seet RCS, Marks RS, Tok AIY. B-Type Natriuretic Peptide as a Significant Brain Biomarker for Stroke Triaging Using a Bedside Point-of-Care Monitoring Biosensor. BIOSENSORS 2020; 10:E107. [PMID: 32859068 PMCID: PMC7559708 DOI: 10.3390/bios10090107] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/13/2020] [Revised: 08/23/2020] [Accepted: 08/24/2020] [Indexed: 05/12/2023]
Abstract
Stroke is a widespread condition that causes 7 million deaths globally. Survivors suffer from a range of disabilities that affect their everyday life. It is a complex condition and there is a need to monitor the different signals that are associated with it. Stroke patients need to be rapidly diagnosed in the emergency department in order to allow the admission of the time-limited treatment of tissue plasminogen activator (tPA). Stroke diagnostics show the use of sophisticated technologies; however, they still contain limitations. The hidden information and technological advancements behind the utilization of biomarkers for stroke triaging are significant. Stroke biomarkers can revolutionize the way stroke patients are diagnosed, monitored, and how they recover. Different biomarkers indicate different cascades and exhibit unique expression patterns which are connected to certain pathologies in the human body. Over the past decades, B-type natriuretic peptide (BNP) and its derivative N-terminal fragment (NT-proBNP) have been increasingly investigated and highlighted as significant cardiovascular biomarkers. This work reviews the recent studies that have reported on the usefulness of BNP and NT-proBNP for stroke triaging. Their classification association is also presented, with increased mortality in stroke, correlation with cardioembolic stroke, and an indication of a second stroke recurrence. Moreover, recent scientific efforts conducted for the technological advancement of a bedside point-of-care (POC) device for BNP and NT-proBNP measurements are discussed. The conclusions presented in this review may hopefully assist in the major efforts that are currently being conducted in order to improve the care of stroke patients.
Collapse
Affiliation(s)
- Dorin Harpaz
- School of Material Science & Engineering, Nanyang Technology University, 50 Nanyang Avenue, Singapore 639798, Singapore;
- Department of Biotechnology Engineering, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel;
| | - Raymond C. S. Seet
- Division of Neurology, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, NUHS Tower Block, 1E Kent Ridge Road, Singapore 119228, Singapore;
| | - Robert S. Marks
- Department of Biotechnology Engineering, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel;
| | - Alfred I. Y. Tok
- School of Material Science & Engineering, Nanyang Technology University, 50 Nanyang Avenue, Singapore 639798, Singapore;
| |
Collapse
|
19
|
Cheah IK, Halliwell B. Could Ergothioneine Aid in the Treatment of Coronavirus Patients? Antioxidants (Basel) 2020; 9:E595. [PMID: 32646061 PMCID: PMC7402156 DOI: 10.3390/antiox9070595] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2020] [Revised: 06/25/2020] [Accepted: 07/02/2020] [Indexed: 01/08/2023] Open
Abstract
Infection with SARS-CoV-2 causes the coronavirus infectious disease 2019 (COVID-19), a pandemic that has, at present, infected more than 11 million people globally. Some COVID-19 patients develop a severe and critical illness, spurred on by excessive inflammation that can lead to respiratory or multiorgan failure. Numerous studies have established the unique array of cytoprotective properties of the dietary amino acid ergothioneine. Based on studies in a range of in vitro and in vivo models, ergothioneine has exhibited the ability to modulate inflammation, scavenge free radicals, protect against acute respiratory distress syndrome, prevent endothelial dysfunction, protect against ischemia and reperfusion injury, protect against neuronal damage, counteract iron dysregulation, hinder lung and liver fibrosis, and mitigate damage to the lungs, kidneys, liver, gastrointestinal tract, and testis, amongst many others. When compiled, this evidence suggests that ergothioneine has a potential application in the treatment of the underlying pathology of COVID-19. We propose that ergothioneine could be used as a therapeutic to reduce the severity and mortality of COVID-19, especially in the elderly and those with underlying health conditions. This review presents evidence to support that proposal.
Collapse
Affiliation(s)
- Irwin K. Cheah
- Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117596, Singapore;
- Life Science Institute, Neurobiology Programme, Centre for Life Sciences, National University of Singapore, Singapore 117456, Singapore
| | - Barry Halliwell
- Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117596, Singapore;
- Life Science Institute, Neurobiology Programme, Centre for Life Sciences, National University of Singapore, Singapore 117456, Singapore
| |
Collapse
|
20
|
Oxidative Stress-Mediated Blood-Brain Barrier (BBB) Disruption in Neurological Diseases. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 2020. [DOI: 10.1155/2020/4356386] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The blood-brain barrier (BBB), as a crucial gate of brain-blood molecular exchange, is involved in the pathogenesis of multiple neurological diseases. Oxidative stress is caused by an imbalance between the production of reactive oxygen species (ROS) and the scavenger system. Since oxidative stress plays a significant role in the production and maintenance of the BBB, the cerebrovascular system is especially vulnerable to it. The pathways that initiate BBB dysfunction include, but are not limited to, mitochondrial dysfunction, excitotoxicity, iron metabolism, cytokines, pyroptosis, and necroptosis, all converging on the generation of ROS. Interestingly, ROS also provide common triggers that directly regulate BBB damage, parameters including tight junction (TJ) modifications, transporters, matrix metalloproteinase (MMP) activation, inflammatory responses, and autophagy. We will discuss the role of oxidative stress-mediated BBB disruption in neurological diseases, such as hemorrhagic stroke, ischemic stroke (IS), Alzheimer’s disease (AD), Parkinson’s disease (PD), traumatic brain injury (TBI), amyotrophic lateral sclerosis (ALS), and cerebral small vessel disease (CSVD). This review will also discuss the latest clinical evidence of potential biomarkers and antioxidant drugs towards oxidative stress in neurological diseases. A deeper understanding of how oxidative stress damages BBB may open up more therapeutic options for the treatment of neurological diseases.
Collapse
|
21
|
Ma N, Yang Y, Liu X, Li S, Qin Z, Li J. Plasma metabonomics and proteomics studies on the anti-thrombosis mechanism of aspirin eugenol ester in rat tail thrombosis model. J Proteomics 2019; 215:103631. [PMID: 31891783 DOI: 10.1016/j.jprot.2019.103631] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2019] [Revised: 12/10/2019] [Accepted: 12/27/2019] [Indexed: 01/09/2023]
Abstract
Aspirin eugenol eater (AEE), a new drug compound, was synthesized through the combination of aspirin and eugenol. Antithrombotic effects of AEE have been confirmed in carrageenan-induced rat tail thrombosis model. However, its mechanism is unclear. With the application of integrated approach combining proteomics and metabolomics, the profilings of protein and metabolite in plasma were examined in thrombosis rat pretreated with AEE, aspirin and eugenol, respectively. A clear separation of the plasma metabolic profiles from different groups was found in score plots. 15 metabolites related with the metabolism of fatty acid, energy and amino acid were found. A total of 144, 38, 41 and 54 differentially abundant proteins (DAPs) were identified in control, AEE, aspirin and eugenol group, respectively. Proteomic results showed that aspirin modulated 7 proteins in amino acid metabolism and 4 proteins in complement system; eugenol regulated the 8 proteins related with coagulation cascades and fibrinogen; AEE improved 3 proteins in TCA cycle and 3 in lipid metabolism. Integrated analysis suggested that AEE improved fatty acid, energy and lipid metabolism to against thrombosis. Results of this study indicated AEE had different action mechanism on thrombosis from aspirin and eugenol, and contribute to understanding the mechanisms of AEE on thrombosis. SIGNIFICANCE: Thrombosis is a threat to human health, and there is an urgent need for new drug. In this study, compared with the model group, plasma metabolic profiles in AEE-treated rats were clearly separated; 15 metabolites and 38 proteins were picked out. These metabolites and proteins may assist in understanding the action mechanism of AEE on thrombosis. The results of plasma metabonomics and proteomics also revealed the different action mechanism among AEE, aspirin and eugenol on thrombosis. This study established the foundation to further evaluate the druggability of AEE on thrombosis treatment.
Collapse
Affiliation(s)
- Ning Ma
- Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, Lanzhou 730050, PR China; College of Veterinary Medicine, Agricultural University of Hebei, Baoding, Hebei 071000, PR China
| | - Yajun Yang
- Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, Lanzhou 730050, PR China
| | - Xiwang Liu
- Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, Lanzhou 730050, PR China
| | - Shihong Li
- Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, Lanzhou 730050, PR China
| | - Zhe Qin
- Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, Lanzhou 730050, PR China
| | - Jianyong Li
- Key Lab of New Animal Drug Project of Gansu Province, Key Lab of Veterinary Pharmaceutical Development, Ministry of Agriculture, Lanzhou Institute of Husbandry and Pharmaceutical Science of Chinese Academy of Agricultural Sciences, Lanzhou 730050, PR China.
| |
Collapse
|
22
|
Lorenzano S, Rost NS, Khan M, Li H, Batista LM, Chutinet A, Green RE, Thankachan TK, Thornell B, Muzikansky A, Arai K, Som AT, Pham LDD, Wu O, Harris GJ, Lo EH, Blumberg JB, Milbury PE, Feske SK, Furie KL. Early molecular oxidative stress biomarkers of ischemic penumbra in acute stroke. Neurology 2019; 93:e1288-e1298. [PMID: 31455665 DOI: 10.1212/wnl.0000000000008158] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2018] [Accepted: 04/28/2019] [Indexed: 01/20/2023] Open
Abstract
OBJECTIVES To assess whether plasma biomarkers of oxidative stress predict diffusion-perfusion mismatch in patients with acute ischemic stroke (AIS). METHODS We measured plasma levels of oxidative stress biomarkers such as F2-isoprostanes (F2-isoPs), total and perchloric acid Oxygen Radical Absorbance Capacity (ORACTOT and ORACPCA), urinary levels of 8-oxo-7,8-dihydro-2'-deoxyguoanosine, and inflammatory and tissue-damage biomarkers (high-sensitivity C-reactive protein, matrix metalloproteinase-2 and -9) in a prospective study of patients with AIS presenting within 9 hours of symptom onset. Diffusion-weighted (DWI) and perfusion-weighted (PWI) MRI sequences were analyzed with a semiautomated volumetric method. Mismatch was defined as baseline mean transit time volume minus DWI volume. A percent mismatch cutoff of >20% was considered clinically significant. A stricter definition of mismatch was also used. Mismatch salvage was the region free of overlap by final infarction. RESULTS Mismatch >20% was present in 153 of 216 (70.8%) patients (mean [±SD] age 69.2 ± 14.3 years, 41.2% women). Patients with mismatch >20% were more likely to have higher baseline plasma levels of ORACPCA (p = 0.020) and F2-isoPs (p = 0.145). Multivariate binary logistic regression demonstrated that lnF2-isoP (odds ratio [OR] 2.44, 95% confidence interval [CI] 1.19-4.98, p = 0.014) and lnORACPCA (OR 4.18, 95% CI 1.41-12.41, p = 0.010) were independent predictors of >20% PWI-DWI mismatch and the stricter mismatch definition, respectively. lnORACTOT significantly predicted mismatch salvage volume (>20% mismatch p = 0.010, stricter mismatch definition p = 0.003). CONCLUSIONS Elevated hyperacute plasma levels of F2-isoP and ORAC are associated with radiographic evidence of mismatch and mismatch salvage in patients with AIS. If validated, these findings may add to our understanding of the role of oxidative stress in cerebral tissue fate during acute ischemia.
Collapse
Affiliation(s)
- Svetlana Lorenzano
- From the J. Philip Kistler Stroke Research Center (S.L., N.S.R., L.M.B., A.C., R.E.G., T.K.T., B.T.), Department of Neurology, and Department of Radiology (H.L., G.J.H.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of Neurology (M.K., K.L.F.), Rhode Island Hospital, Alpert Medical School of Brown University, Providence; Massachusetts General Hospital Biostatistics Center (A.M.), Boston; Neuroprotection Research Laboratory (K.A., A.T.S., L.-D.D.P., E.H.L.), Neuroscience Center, Departments of Neurology and Radiology, Massachusetts General Hospital and Harvard Medical School; Athinoula A. Martinos Center for Biomedical Imaging (O.W.), Massachusetts General Hospital and Harvard Medical School, Charlestown; Antioxidant Research Laboratory (J.B.B.), Jean Mayer USDA Human Nutrition Research Center on Aging, and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University; and Department of Neurology (S.K.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
| | - Natalia S Rost
- From the J. Philip Kistler Stroke Research Center (S.L., N.S.R., L.M.B., A.C., R.E.G., T.K.T., B.T.), Department of Neurology, and Department of Radiology (H.L., G.J.H.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of Neurology (M.K., K.L.F.), Rhode Island Hospital, Alpert Medical School of Brown University, Providence; Massachusetts General Hospital Biostatistics Center (A.M.), Boston; Neuroprotection Research Laboratory (K.A., A.T.S., L.-D.D.P., E.H.L.), Neuroscience Center, Departments of Neurology and Radiology, Massachusetts General Hospital and Harvard Medical School; Athinoula A. Martinos Center for Biomedical Imaging (O.W.), Massachusetts General Hospital and Harvard Medical School, Charlestown; Antioxidant Research Laboratory (J.B.B.), Jean Mayer USDA Human Nutrition Research Center on Aging, and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University; and Department of Neurology (S.K.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Muhib Khan
- From the J. Philip Kistler Stroke Research Center (S.L., N.S.R., L.M.B., A.C., R.E.G., T.K.T., B.T.), Department of Neurology, and Department of Radiology (H.L., G.J.H.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of Neurology (M.K., K.L.F.), Rhode Island Hospital, Alpert Medical School of Brown University, Providence; Massachusetts General Hospital Biostatistics Center (A.M.), Boston; Neuroprotection Research Laboratory (K.A., A.T.S., L.-D.D.P., E.H.L.), Neuroscience Center, Departments of Neurology and Radiology, Massachusetts General Hospital and Harvard Medical School; Athinoula A. Martinos Center for Biomedical Imaging (O.W.), Massachusetts General Hospital and Harvard Medical School, Charlestown; Antioxidant Research Laboratory (J.B.B.), Jean Mayer USDA Human Nutrition Research Center on Aging, and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University; and Department of Neurology (S.K.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Hua Li
- From the J. Philip Kistler Stroke Research Center (S.L., N.S.R., L.M.B., A.C., R.E.G., T.K.T., B.T.), Department of Neurology, and Department of Radiology (H.L., G.J.H.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of Neurology (M.K., K.L.F.), Rhode Island Hospital, Alpert Medical School of Brown University, Providence; Massachusetts General Hospital Biostatistics Center (A.M.), Boston; Neuroprotection Research Laboratory (K.A., A.T.S., L.-D.D.P., E.H.L.), Neuroscience Center, Departments of Neurology and Radiology, Massachusetts General Hospital and Harvard Medical School; Athinoula A. Martinos Center for Biomedical Imaging (O.W.), Massachusetts General Hospital and Harvard Medical School, Charlestown; Antioxidant Research Laboratory (J.B.B.), Jean Mayer USDA Human Nutrition Research Center on Aging, and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University; and Department of Neurology (S.K.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Leonardo M Batista
- From the J. Philip Kistler Stroke Research Center (S.L., N.S.R., L.M.B., A.C., R.E.G., T.K.T., B.T.), Department of Neurology, and Department of Radiology (H.L., G.J.H.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of Neurology (M.K., K.L.F.), Rhode Island Hospital, Alpert Medical School of Brown University, Providence; Massachusetts General Hospital Biostatistics Center (A.M.), Boston; Neuroprotection Research Laboratory (K.A., A.T.S., L.-D.D.P., E.H.L.), Neuroscience Center, Departments of Neurology and Radiology, Massachusetts General Hospital and Harvard Medical School; Athinoula A. Martinos Center for Biomedical Imaging (O.W.), Massachusetts General Hospital and Harvard Medical School, Charlestown; Antioxidant Research Laboratory (J.B.B.), Jean Mayer USDA Human Nutrition Research Center on Aging, and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University; and Department of Neurology (S.K.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Aurauma Chutinet
- From the J. Philip Kistler Stroke Research Center (S.L., N.S.R., L.M.B., A.C., R.E.G., T.K.T., B.T.), Department of Neurology, and Department of Radiology (H.L., G.J.H.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of Neurology (M.K., K.L.F.), Rhode Island Hospital, Alpert Medical School of Brown University, Providence; Massachusetts General Hospital Biostatistics Center (A.M.), Boston; Neuroprotection Research Laboratory (K.A., A.T.S., L.-D.D.P., E.H.L.), Neuroscience Center, Departments of Neurology and Radiology, Massachusetts General Hospital and Harvard Medical School; Athinoula A. Martinos Center for Biomedical Imaging (O.W.), Massachusetts General Hospital and Harvard Medical School, Charlestown; Antioxidant Research Laboratory (J.B.B.), Jean Mayer USDA Human Nutrition Research Center on Aging, and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University; and Department of Neurology (S.K.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Rebecca E Green
- From the J. Philip Kistler Stroke Research Center (S.L., N.S.R., L.M.B., A.C., R.E.G., T.K.T., B.T.), Department of Neurology, and Department of Radiology (H.L., G.J.H.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of Neurology (M.K., K.L.F.), Rhode Island Hospital, Alpert Medical School of Brown University, Providence; Massachusetts General Hospital Biostatistics Center (A.M.), Boston; Neuroprotection Research Laboratory (K.A., A.T.S., L.-D.D.P., E.H.L.), Neuroscience Center, Departments of Neurology and Radiology, Massachusetts General Hospital and Harvard Medical School; Athinoula A. Martinos Center for Biomedical Imaging (O.W.), Massachusetts General Hospital and Harvard Medical School, Charlestown; Antioxidant Research Laboratory (J.B.B.), Jean Mayer USDA Human Nutrition Research Center on Aging, and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University; and Department of Neurology (S.K.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Tijy K Thankachan
- From the J. Philip Kistler Stroke Research Center (S.L., N.S.R., L.M.B., A.C., R.E.G., T.K.T., B.T.), Department of Neurology, and Department of Radiology (H.L., G.J.H.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of Neurology (M.K., K.L.F.), Rhode Island Hospital, Alpert Medical School of Brown University, Providence; Massachusetts General Hospital Biostatistics Center (A.M.), Boston; Neuroprotection Research Laboratory (K.A., A.T.S., L.-D.D.P., E.H.L.), Neuroscience Center, Departments of Neurology and Radiology, Massachusetts General Hospital and Harvard Medical School; Athinoula A. Martinos Center for Biomedical Imaging (O.W.), Massachusetts General Hospital and Harvard Medical School, Charlestown; Antioxidant Research Laboratory (J.B.B.), Jean Mayer USDA Human Nutrition Research Center on Aging, and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University; and Department of Neurology (S.K.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Brenda Thornell
- From the J. Philip Kistler Stroke Research Center (S.L., N.S.R., L.M.B., A.C., R.E.G., T.K.T., B.T.), Department of Neurology, and Department of Radiology (H.L., G.J.H.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of Neurology (M.K., K.L.F.), Rhode Island Hospital, Alpert Medical School of Brown University, Providence; Massachusetts General Hospital Biostatistics Center (A.M.), Boston; Neuroprotection Research Laboratory (K.A., A.T.S., L.-D.D.P., E.H.L.), Neuroscience Center, Departments of Neurology and Radiology, Massachusetts General Hospital and Harvard Medical School; Athinoula A. Martinos Center for Biomedical Imaging (O.W.), Massachusetts General Hospital and Harvard Medical School, Charlestown; Antioxidant Research Laboratory (J.B.B.), Jean Mayer USDA Human Nutrition Research Center on Aging, and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University; and Department of Neurology (S.K.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Alona Muzikansky
- From the J. Philip Kistler Stroke Research Center (S.L., N.S.R., L.M.B., A.C., R.E.G., T.K.T., B.T.), Department of Neurology, and Department of Radiology (H.L., G.J.H.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of Neurology (M.K., K.L.F.), Rhode Island Hospital, Alpert Medical School of Brown University, Providence; Massachusetts General Hospital Biostatistics Center (A.M.), Boston; Neuroprotection Research Laboratory (K.A., A.T.S., L.-D.D.P., E.H.L.), Neuroscience Center, Departments of Neurology and Radiology, Massachusetts General Hospital and Harvard Medical School; Athinoula A. Martinos Center for Biomedical Imaging (O.W.), Massachusetts General Hospital and Harvard Medical School, Charlestown; Antioxidant Research Laboratory (J.B.B.), Jean Mayer USDA Human Nutrition Research Center on Aging, and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University; and Department of Neurology (S.K.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Ken Arai
- From the J. Philip Kistler Stroke Research Center (S.L., N.S.R., L.M.B., A.C., R.E.G., T.K.T., B.T.), Department of Neurology, and Department of Radiology (H.L., G.J.H.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of Neurology (M.K., K.L.F.), Rhode Island Hospital, Alpert Medical School of Brown University, Providence; Massachusetts General Hospital Biostatistics Center (A.M.), Boston; Neuroprotection Research Laboratory (K.A., A.T.S., L.-D.D.P., E.H.L.), Neuroscience Center, Departments of Neurology and Radiology, Massachusetts General Hospital and Harvard Medical School; Athinoula A. Martinos Center for Biomedical Imaging (O.W.), Massachusetts General Hospital and Harvard Medical School, Charlestown; Antioxidant Research Laboratory (J.B.B.), Jean Mayer USDA Human Nutrition Research Center on Aging, and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University; and Department of Neurology (S.K.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Angel T Som
- From the J. Philip Kistler Stroke Research Center (S.L., N.S.R., L.M.B., A.C., R.E.G., T.K.T., B.T.), Department of Neurology, and Department of Radiology (H.L., G.J.H.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of Neurology (M.K., K.L.F.), Rhode Island Hospital, Alpert Medical School of Brown University, Providence; Massachusetts General Hospital Biostatistics Center (A.M.), Boston; Neuroprotection Research Laboratory (K.A., A.T.S., L.-D.D.P., E.H.L.), Neuroscience Center, Departments of Neurology and Radiology, Massachusetts General Hospital and Harvard Medical School; Athinoula A. Martinos Center for Biomedical Imaging (O.W.), Massachusetts General Hospital and Harvard Medical School, Charlestown; Antioxidant Research Laboratory (J.B.B.), Jean Mayer USDA Human Nutrition Research Center on Aging, and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University; and Department of Neurology (S.K.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Loc-Duyen D Pham
- From the J. Philip Kistler Stroke Research Center (S.L., N.S.R., L.M.B., A.C., R.E.G., T.K.T., B.T.), Department of Neurology, and Department of Radiology (H.L., G.J.H.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of Neurology (M.K., K.L.F.), Rhode Island Hospital, Alpert Medical School of Brown University, Providence; Massachusetts General Hospital Biostatistics Center (A.M.), Boston; Neuroprotection Research Laboratory (K.A., A.T.S., L.-D.D.P., E.H.L.), Neuroscience Center, Departments of Neurology and Radiology, Massachusetts General Hospital and Harvard Medical School; Athinoula A. Martinos Center for Biomedical Imaging (O.W.), Massachusetts General Hospital and Harvard Medical School, Charlestown; Antioxidant Research Laboratory (J.B.B.), Jean Mayer USDA Human Nutrition Research Center on Aging, and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University; and Department of Neurology (S.K.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Ona Wu
- From the J. Philip Kistler Stroke Research Center (S.L., N.S.R., L.M.B., A.C., R.E.G., T.K.T., B.T.), Department of Neurology, and Department of Radiology (H.L., G.J.H.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of Neurology (M.K., K.L.F.), Rhode Island Hospital, Alpert Medical School of Brown University, Providence; Massachusetts General Hospital Biostatistics Center (A.M.), Boston; Neuroprotection Research Laboratory (K.A., A.T.S., L.-D.D.P., E.H.L.), Neuroscience Center, Departments of Neurology and Radiology, Massachusetts General Hospital and Harvard Medical School; Athinoula A. Martinos Center for Biomedical Imaging (O.W.), Massachusetts General Hospital and Harvard Medical School, Charlestown; Antioxidant Research Laboratory (J.B.B.), Jean Mayer USDA Human Nutrition Research Center on Aging, and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University; and Department of Neurology (S.K.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Gordon J Harris
- From the J. Philip Kistler Stroke Research Center (S.L., N.S.R., L.M.B., A.C., R.E.G., T.K.T., B.T.), Department of Neurology, and Department of Radiology (H.L., G.J.H.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of Neurology (M.K., K.L.F.), Rhode Island Hospital, Alpert Medical School of Brown University, Providence; Massachusetts General Hospital Biostatistics Center (A.M.), Boston; Neuroprotection Research Laboratory (K.A., A.T.S., L.-D.D.P., E.H.L.), Neuroscience Center, Departments of Neurology and Radiology, Massachusetts General Hospital and Harvard Medical School; Athinoula A. Martinos Center for Biomedical Imaging (O.W.), Massachusetts General Hospital and Harvard Medical School, Charlestown; Antioxidant Research Laboratory (J.B.B.), Jean Mayer USDA Human Nutrition Research Center on Aging, and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University; and Department of Neurology (S.K.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Eng H Lo
- From the J. Philip Kistler Stroke Research Center (S.L., N.S.R., L.M.B., A.C., R.E.G., T.K.T., B.T.), Department of Neurology, and Department of Radiology (H.L., G.J.H.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of Neurology (M.K., K.L.F.), Rhode Island Hospital, Alpert Medical School of Brown University, Providence; Massachusetts General Hospital Biostatistics Center (A.M.), Boston; Neuroprotection Research Laboratory (K.A., A.T.S., L.-D.D.P., E.H.L.), Neuroscience Center, Departments of Neurology and Radiology, Massachusetts General Hospital and Harvard Medical School; Athinoula A. Martinos Center for Biomedical Imaging (O.W.), Massachusetts General Hospital and Harvard Medical School, Charlestown; Antioxidant Research Laboratory (J.B.B.), Jean Mayer USDA Human Nutrition Research Center on Aging, and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University; and Department of Neurology (S.K.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
| | - Jeffrey B Blumberg
- From the J. Philip Kistler Stroke Research Center (S.L., N.S.R., L.M.B., A.C., R.E.G., T.K.T., B.T.), Department of Neurology, and Department of Radiology (H.L., G.J.H.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of Neurology (M.K., K.L.F.), Rhode Island Hospital, Alpert Medical School of Brown University, Providence; Massachusetts General Hospital Biostatistics Center (A.M.), Boston; Neuroprotection Research Laboratory (K.A., A.T.S., L.-D.D.P., E.H.L.), Neuroscience Center, Departments of Neurology and Radiology, Massachusetts General Hospital and Harvard Medical School; Athinoula A. Martinos Center for Biomedical Imaging (O.W.), Massachusetts General Hospital and Harvard Medical School, Charlestown; Antioxidant Research Laboratory (J.B.B.), Jean Mayer USDA Human Nutrition Research Center on Aging, and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University; and Department of Neurology (S.K.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Paul E Milbury
- From the J. Philip Kistler Stroke Research Center (S.L., N.S.R., L.M.B., A.C., R.E.G., T.K.T., B.T.), Department of Neurology, and Department of Radiology (H.L., G.J.H.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of Neurology (M.K., K.L.F.), Rhode Island Hospital, Alpert Medical School of Brown University, Providence; Massachusetts General Hospital Biostatistics Center (A.M.), Boston; Neuroprotection Research Laboratory (K.A., A.T.S., L.-D.D.P., E.H.L.), Neuroscience Center, Departments of Neurology and Radiology, Massachusetts General Hospital and Harvard Medical School; Athinoula A. Martinos Center for Biomedical Imaging (O.W.), Massachusetts General Hospital and Harvard Medical School, Charlestown; Antioxidant Research Laboratory (J.B.B.), Jean Mayer USDA Human Nutrition Research Center on Aging, and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University; and Department of Neurology (S.K.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Steven K Feske
- From the J. Philip Kistler Stroke Research Center (S.L., N.S.R., L.M.B., A.C., R.E.G., T.K.T., B.T.), Department of Neurology, and Department of Radiology (H.L., G.J.H.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of Neurology (M.K., K.L.F.), Rhode Island Hospital, Alpert Medical School of Brown University, Providence; Massachusetts General Hospital Biostatistics Center (A.M.), Boston; Neuroprotection Research Laboratory (K.A., A.T.S., L.-D.D.P., E.H.L.), Neuroscience Center, Departments of Neurology and Radiology, Massachusetts General Hospital and Harvard Medical School; Athinoula A. Martinos Center for Biomedical Imaging (O.W.), Massachusetts General Hospital and Harvard Medical School, Charlestown; Antioxidant Research Laboratory (J.B.B.), Jean Mayer USDA Human Nutrition Research Center on Aging, and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University; and Department of Neurology (S.K.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Karen L Furie
- From the J. Philip Kistler Stroke Research Center (S.L., N.S.R., L.M.B., A.C., R.E.G., T.K.T., B.T.), Department of Neurology, and Department of Radiology (H.L., G.J.H.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of Neurology (M.K., K.L.F.), Rhode Island Hospital, Alpert Medical School of Brown University, Providence; Massachusetts General Hospital Biostatistics Center (A.M.), Boston; Neuroprotection Research Laboratory (K.A., A.T.S., L.-D.D.P., E.H.L.), Neuroscience Center, Departments of Neurology and Radiology, Massachusetts General Hospital and Harvard Medical School; Athinoula A. Martinos Center for Biomedical Imaging (O.W.), Massachusetts General Hospital and Harvard Medical School, Charlestown; Antioxidant Research Laboratory (J.B.B.), Jean Mayer USDA Human Nutrition Research Center on Aging, and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University; and Department of Neurology (S.K.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| |
Collapse
|
23
|
Calzada M, López N, Noguera JA, Mendiola J, Torres AM. Elevation of isoprostanes in polycystic ovary syndrome and its relationship with cardiovascular risk factors. J Endocrinol Invest 2019; 42:75-83. [PMID: 29687417 DOI: 10.1007/s40618-018-0888-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/06/2017] [Accepted: 04/10/2018] [Indexed: 12/30/2022]
Abstract
PURPOSE To evaluate the plasma level of 8-isoprostanes in women with polycystic ovary syndrome. To also investigate whether there is a relationship between 8-isoprostanes and several cardiovascular risk factors. METHODS A total of 125 women with polycystic ovary syndrome and 169 healthy women were enrolled in this case-control study. 8-Isoprostanes and different parameters were measured in all subjects. Patients were evaluated for the presence of polycystic ovary syndrome according to the Rotterdam Consensus Conference criteria. RESULTS 8-Isoprostanes levels were significantly higher in patients with polycystic ovary syndrome (138.4 ± 104.1 pg/mL) compared with control group (68.6 ± 34.3 pg/mL) (p < 0.001). The mean of triglycerides, lipid accumulation product, C-reactive protein, homocysteine, insulin, and homeostatic model assessment for insulin resistance were significantly higher in polycystic ovary syndrome patients with high 8-isoprostanes than those with normal 8-isoprostanes (p < 0.05). The Pearson correlation analyses showed that 8-isoprostanes levels in polycystic ovary syndrome group had a positive correlation with waist circumference, triglycerides, low-density lipoprotein cholesterol, apolipoprotein B, homocysteine, insulin, homeostatic model assessment for insulin resistance. CONCLUSIONS Patients with polycystic ovary syndrome have higher 8-isoprostanes levels and it is associated with several cardiovascular risk factors.
Collapse
Affiliation(s)
- M Calzada
- Clinical Analysis Service, Hospital University "Virgen de la Arrixaca", Ctra. Madrid-Cartagena, s/n, El Palmar, 30120, Murcia, Spain.
| | - N López
- Clinical Analysis Service, Hospital University "Virgen de la Arrixaca", Ctra. Madrid-Cartagena, s/n, El Palmar, 30120, Murcia, Spain
| | - J A Noguera
- Clinical Analysis Service, Hospital University "Virgen de la Arrixaca", Ctra. Madrid-Cartagena, s/n, El Palmar, 30120, Murcia, Spain
| | - J Mendiola
- Division of Preventive Medicine and Public Health, Department of Health and Social Sciences, University of Murcia, Murcia, Spain
| | - A M Torres
- Division of Preventive Medicine and Public Health, Department of Health and Social Sciences, University of Murcia, Murcia, Spain
| |
Collapse
|
24
|
Turner R, Brennan SO, Ashby LV, Dickerhof N, Hamzah MR, Pearson JF, Stamp LK, Kettle AJ. Conjugation of urate-derived electrophiles to proteins during normal metabolism and inflammation. J Biol Chem 2018; 293:19886-19898. [PMID: 30385504 DOI: 10.1074/jbc.ra118.005237] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2018] [Revised: 10/31/2018] [Indexed: 12/19/2022] Open
Abstract
Urate is often viewed as an antioxidant. Here, we present an alternative perspective by showing that, when oxidized, urate propagates oxidative stress. Oxidation converts urate to the urate radical and the electrophilic products dehydrourate, 5-hydroxyisourate, and urate hydroperoxide, which eventually break down to allantoin. We investigated whether urate-derived electrophiles are intercepted by nucleophilic amino acid residues to form stable adducts on proteins. When urate was oxidized in the presence of various peptides and proteins, two adducts derived from urate (M r 167 Da) were detected and had mass additions of 140 and 166 Da, occurring mainly on lysine residues and N-terminal amines. The adduct with a 140-Da mass addition was detected more frequently and was stable. Dehydrourate (M r 166 Da) also formed transient adducts with cysteine residues. Urate-derived adducts were detected on human serum albumin in plasma of healthy donors. Basal adduct levels increased when neutrophils were added to plasma and stimulated, and relied on the NADPH oxidase, myeloperoxidase, hydrogen peroxide, and superoxide. Adducts of oxidized urate on serum albumin were elevated in plasma and synovial fluid from individuals with gout and rheumatoid arthritis. We propose that rather than acting as an antioxidant, urate's conversion to electrophiles contributes to oxidative stress. The addition of urate-derived electrophiles to nucleophilic amino acid residues, a process we call oxidative uratylation, will leave a footprint on proteins that could alter their function when critical sites are modified.
Collapse
Affiliation(s)
- Rufus Turner
- From the Centre for Free Radical Research.,the Department of Pathology and Biomedical Science
| | | | - Louisa V Ashby
- From the Centre for Free Radical Research.,the Department of Pathology and Biomedical Science
| | - Nina Dickerhof
- From the Centre for Free Radical Research.,the Department of Pathology and Biomedical Science
| | - Melanie R Hamzah
- From the Centre for Free Radical Research.,the Department of Pathology and Biomedical Science
| | | | - Lisa K Stamp
- the Department of Medicine, University of Otago Christchurch, P.O. Box 4345, Christchurch 8011, New Zealand
| | - Anthony J Kettle
- From the Centre for Free Radical Research, .,the Department of Pathology and Biomedical Science
| |
Collapse
|
25
|
Niki E. Oxidant-specific biomarkers of oxidative stress. Association with atherosclerosis and implication for antioxidant effects. Free Radic Biol Med 2018; 120:425-440. [PMID: 29625172 DOI: 10.1016/j.freeradbiomed.2018.04.001] [Citation(s) in RCA: 49] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/18/2018] [Revised: 03/30/2018] [Accepted: 04/02/2018] [Indexed: 12/16/2022]
Abstract
The unregulated oxidative modification of lipids, proteins, and nucleic acids induced by multiple oxidants has been implicated in the pathogenesis of many diseases. Antioxidants with diverse functions exert their roles either directly or indirectly in the physiological defense network to inhibit such deleterious oxidative modification of biological molecules and resulting damage. The efficacy of antioxidants depends on the nature of oxidants. Therefore, it is important to identify the oxidants which are responsible for modification of biological molecules. Some oxidation products produced selectively by specific oxidant enable to identify the responsible oxidants, while other products are produced by several oxidants similarly. In this review article, several oxidant-specific products produced selectively by peroxyl radicals, peroxynitrite, hypochlorous acid, lipoxygenase, and singlet oxygen were summarized and their potential role as biomarker is discussed. It is shown that the levels of specific oxidation products including hydroxylinoleate isomers, nitrated and chlorinated products, and oxysterols produced by the above-mentioned oxidants are elevated in the human atherosclerotic lesions, suggesting that all these oxidants may contribute to the development of atherosclerosis. Further, it was shown that the reactivities of physiological antioxidants toward the above-mentioned oxidants vary extensively, suggesting that multiple antioxidants effective against these different oxidants are required, since no single antioxidant alone can cope with these multiple oxidants.
Collapse
Affiliation(s)
- Etsuo Niki
- National Institute of Advanced Industrial Science & Technology, Takamatsu 761-0395, Japan.
| |
Collapse
|
26
|
Signorini C, De Felice C, Durand T, Galano JM, Oger C, Leoncini S, Ciccoli L, Carone M, Ulivelli M, Manna C, Cortelazzo A, Lee JCY, Hayek J. Relevance of 4-F 4t-neuroprostane and 10-F 4t-neuroprostane to neurological diseases. Free Radic Biol Med 2018; 115:278-287. [PMID: 29233794 DOI: 10.1016/j.freeradbiomed.2017.12.009] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/26/2017] [Revised: 11/16/2017] [Accepted: 12/06/2017] [Indexed: 12/11/2022]
Abstract
F4-neuroprostanes (F4-NeuroPs) are non-enzymatic oxidized products derived from docosahexaenoic acid (DHA) and are suggested to be oxidative damage biomarkers of neurological diseases. However, 128 isomers can be formed from DHA oxidation and among them, 4(RS)-4-F4t-NeuroP (4-F4t-NeuroP) and 10(RS)-10-F4t-NeuroP (10-F4t-NeuroP) are the most studied. Here, we report the identification and the clinical relevance of 4-F4t-NeuroP and 10-F4t-NeuroP in plasma of four different neurological diseases, including multiple sclerosis (MS), autism spectrum disorders (ASD), Rett syndrome (RTT), and Down syndrome (DS). The identification and the optimization of the method were carried out by gas chromatography/negative-ion chemical ionization tandem mass spectrometry (GC/NICI-MS/MS) using chemically synthesized 4-F4t-NeuroP and 10-F4t-NeuroP standards and in oxidized DHA liposome. Both 4-F4t-NeuroP and 10-F4t-NeuroP were detectable in all plasma samples from MS (n = 16), DS (n = 16), ASD (n = 9) and RTT (n = 20) patients. While plasma 10-F4t-NeuroP content was significantly higher in patients of all diseases as compared to age and gender matched healthy control subjects (n = 61), 4-F4t-NeuroP levels were significantly higher in MS and RTT as compared to healthy controls. Significant positive relationships were observed between relative disease severity and 4-F4t-NeuroP levels (r = 0.469, P <0.0001), and 10-F4t-NeuroP levels (r = 0.757, P < 0.0001). The study showed that the plasma amount ratio of 10-F4t-NeuroP to 4-F4t-NeuroP and the plasma amount as individual isomer can be used to discriminate between different brain diseases. Overall, by comparing the different types of disease, our plasma data indicates that 4-F4t-NeuroP and 10-F4t -NeuroP: i) are biologically synthesized in vivo and circulated, ii) are related to clinical severity of neurological diseases, iii) are useful to identify shared pathogenetic pathways in distinct brain diseases, and iv) appears to be distinctive for different neurological conditions, thus representing potentially new biological disease markers. Our data strongly suggest that in vivo DHA oxidation follows preferential chemical rearrangements according to different brain diseases.
Collapse
Affiliation(s)
- Cinzia Signorini
- Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy
| | - Claudio De Felice
- Neonatal Intensive Care Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy
| | - Thierry Durand
- Institut des Biomolécules Max Mousseron, (IBMM), UMR 5247, CNRS, Université de Montpellier, ENSCM, Montpellier, France
| | - Jean-Marie Galano
- Institut des Biomolécules Max Mousseron, (IBMM), UMR 5247, CNRS, Université de Montpellier, ENSCM, Montpellier, France
| | - Camille Oger
- Institut des Biomolécules Max Mousseron, (IBMM), UMR 5247, CNRS, Université de Montpellier, ENSCM, Montpellier, France
| | - Silvia Leoncini
- Child Neuropsychiatry Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy
| | - Lucia Ciccoli
- Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy
| | - Marisa Carone
- Department of Medicine, Surgery, and Neuroscience, University of Siena, Siena, Italy
| | - Monica Ulivelli
- Department of Medicine, Surgery, and Neuroscience, University of Siena, Siena, Italy
| | - Caterina Manna
- Department of Biochemistry, Biophysics and General Pathology, University of Campania "Luigi Vanvitelli", Naples, Italy"
| | - Alessio Cortelazzo
- Child Neuropsychiatry Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy; Clinical Pathology Laboratory Unit, University Hospital, AOUS, Siena, Italy
| | - Jetty Chung-Yung Lee
- The University of Hong Kong, School of Biological Sciences, Hong Kong Special Administrative Region
| | - Joussef Hayek
- Child Neuropsychiatry Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy
| |
Collapse
|
27
|
Lorenzano S, Rost NS, Khan M, Li H, Lima FO, Maas MB, Green RE, Thankachan TK, Dipietro AJ, Arai K, Som AT, Pham LDD, Wu O, Harris GJ, Lo EH, Blumberg JB, Milbury PE, Feske SK, Furie KL. Oxidative Stress Biomarkers of Brain Damage: Hyperacute Plasma F2-Isoprostane Predicts Infarct Growth in Stroke. Stroke 2018; 49:630-637. [PMID: 29371434 DOI: 10.1161/strokeaha.117.018440] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2017] [Revised: 11/07/2017] [Accepted: 11/30/2017] [Indexed: 02/04/2023]
Abstract
BACKGROUND AND PURPOSE Oxidative stress is an early response to cerebral ischemia and is likely to play an important role in the pathogenesis of cerebral ischemic injury. We sought to evaluate whether hyperacute plasma concentrations of biomarkers of oxidative stress, inflammation, and tissue damage predict infarct growth (IG). METHODS We prospectively measured plasma F2-isoprostane (F2-isoP), urinary 8-oxo-7,8-dihydro-2'-deoxyguoanosine, plasma oxygen radical absorbance capacity assay, high sensitivity C reactive protein, and matrix metalloproteinase 2 and 9 in consecutive patients with acute ischemic stroke presenting within 9 hours of symptom onset. Patients with baseline diffusion-weighted magnetic resonance imaging and follow-up diffusion-weighted imaging or computed tomographic scan were included to evaluate the final infarct volume. Baseline diffusion-weighted imaging volume and final infarct volume were analyzed using semiautomated volumetric method. IG volume was defined as the difference between final infarct volume and baseline diffusion-weighted imaging volume. RESULTS A total of 220 acute ischemic stroke subjects were included in the final analysis. One hundred seventy of these had IG. Baseline F2-isoP significantly correlated with IG volume (Spearman ρ=0.20; P=0.005) and final infarct volume (Spearman ρ=0.19; P=0.009). In a multivariate binary logistic regression model, baseline F2-isoP emerged as an independent predictor of the occurrence of IG (odds ratio, 2.57; 95% confidence interval, 1.37-4.83; P=0.007). In a multivariate linear regression model, baseline F2-isoP was independently associated with IG volume (B, 0.38; 95% confidence interval, 0.04-0.72; P=0.03). CONCLUSIONS Elevated hyperacute plasma F2-isoP concentrations independently predict the occurrence of IG and IG volume in patients with acute ischemic stroke. If validated in future studies, measuring plasma F2-isoP might be helpful in the acute setting to stratify patients with acute ischemic stroke for relative severity of ischemic injury and expected progression.
Collapse
Affiliation(s)
- Svetlana Lorenzano
- From the J. Philip Kistler Stroke Research Center, Department of Neurology (S.L., N.S.R., F.O.L., M.B.M., R.E.G., T.K.T., A.J.D.), Department of Radiology (H.L., G.J.H.), and Neuroprotection Research Laboratory, Neuroscience Center, Departments of Neurology and Radiology (K.A., A.T.S., L.-D.D.P., E.H.L.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Neurology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence (M.K., K.L.F.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown (O.W.); Antioxidant Research Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging (J.B.B.) and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University, Boston, MA; and Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.K.F.).
| | - Natalia S Rost
- From the J. Philip Kistler Stroke Research Center, Department of Neurology (S.L., N.S.R., F.O.L., M.B.M., R.E.G., T.K.T., A.J.D.), Department of Radiology (H.L., G.J.H.), and Neuroprotection Research Laboratory, Neuroscience Center, Departments of Neurology and Radiology (K.A., A.T.S., L.-D.D.P., E.H.L.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Neurology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence (M.K., K.L.F.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown (O.W.); Antioxidant Research Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging (J.B.B.) and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University, Boston, MA; and Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.K.F.)
| | - Muhib Khan
- From the J. Philip Kistler Stroke Research Center, Department of Neurology (S.L., N.S.R., F.O.L., M.B.M., R.E.G., T.K.T., A.J.D.), Department of Radiology (H.L., G.J.H.), and Neuroprotection Research Laboratory, Neuroscience Center, Departments of Neurology and Radiology (K.A., A.T.S., L.-D.D.P., E.H.L.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Neurology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence (M.K., K.L.F.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown (O.W.); Antioxidant Research Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging (J.B.B.) and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University, Boston, MA; and Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.K.F.)
| | - Hua Li
- From the J. Philip Kistler Stroke Research Center, Department of Neurology (S.L., N.S.R., F.O.L., M.B.M., R.E.G., T.K.T., A.J.D.), Department of Radiology (H.L., G.J.H.), and Neuroprotection Research Laboratory, Neuroscience Center, Departments of Neurology and Radiology (K.A., A.T.S., L.-D.D.P., E.H.L.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Neurology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence (M.K., K.L.F.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown (O.W.); Antioxidant Research Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging (J.B.B.) and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University, Boston, MA; and Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.K.F.)
| | - Fabricio O Lima
- From the J. Philip Kistler Stroke Research Center, Department of Neurology (S.L., N.S.R., F.O.L., M.B.M., R.E.G., T.K.T., A.J.D.), Department of Radiology (H.L., G.J.H.), and Neuroprotection Research Laboratory, Neuroscience Center, Departments of Neurology and Radiology (K.A., A.T.S., L.-D.D.P., E.H.L.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Neurology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence (M.K., K.L.F.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown (O.W.); Antioxidant Research Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging (J.B.B.) and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University, Boston, MA; and Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.K.F.)
| | - Matthew B Maas
- From the J. Philip Kistler Stroke Research Center, Department of Neurology (S.L., N.S.R., F.O.L., M.B.M., R.E.G., T.K.T., A.J.D.), Department of Radiology (H.L., G.J.H.), and Neuroprotection Research Laboratory, Neuroscience Center, Departments of Neurology and Radiology (K.A., A.T.S., L.-D.D.P., E.H.L.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Neurology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence (M.K., K.L.F.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown (O.W.); Antioxidant Research Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging (J.B.B.) and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University, Boston, MA; and Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.K.F.)
| | - Rebecca E Green
- From the J. Philip Kistler Stroke Research Center, Department of Neurology (S.L., N.S.R., F.O.L., M.B.M., R.E.G., T.K.T., A.J.D.), Department of Radiology (H.L., G.J.H.), and Neuroprotection Research Laboratory, Neuroscience Center, Departments of Neurology and Radiology (K.A., A.T.S., L.-D.D.P., E.H.L.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Neurology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence (M.K., K.L.F.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown (O.W.); Antioxidant Research Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging (J.B.B.) and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University, Boston, MA; and Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.K.F.)
| | - Tijy K Thankachan
- From the J. Philip Kistler Stroke Research Center, Department of Neurology (S.L., N.S.R., F.O.L., M.B.M., R.E.G., T.K.T., A.J.D.), Department of Radiology (H.L., G.J.H.), and Neuroprotection Research Laboratory, Neuroscience Center, Departments of Neurology and Radiology (K.A., A.T.S., L.-D.D.P., E.H.L.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Neurology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence (M.K., K.L.F.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown (O.W.); Antioxidant Research Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging (J.B.B.) and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University, Boston, MA; and Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.K.F.)
| | - Allison J Dipietro
- From the J. Philip Kistler Stroke Research Center, Department of Neurology (S.L., N.S.R., F.O.L., M.B.M., R.E.G., T.K.T., A.J.D.), Department of Radiology (H.L., G.J.H.), and Neuroprotection Research Laboratory, Neuroscience Center, Departments of Neurology and Radiology (K.A., A.T.S., L.-D.D.P., E.H.L.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Neurology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence (M.K., K.L.F.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown (O.W.); Antioxidant Research Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging (J.B.B.) and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University, Boston, MA; and Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.K.F.)
| | - Ken Arai
- From the J. Philip Kistler Stroke Research Center, Department of Neurology (S.L., N.S.R., F.O.L., M.B.M., R.E.G., T.K.T., A.J.D.), Department of Radiology (H.L., G.J.H.), and Neuroprotection Research Laboratory, Neuroscience Center, Departments of Neurology and Radiology (K.A., A.T.S., L.-D.D.P., E.H.L.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Neurology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence (M.K., K.L.F.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown (O.W.); Antioxidant Research Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging (J.B.B.) and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University, Boston, MA; and Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.K.F.)
| | - Angel T Som
- From the J. Philip Kistler Stroke Research Center, Department of Neurology (S.L., N.S.R., F.O.L., M.B.M., R.E.G., T.K.T., A.J.D.), Department of Radiology (H.L., G.J.H.), and Neuroprotection Research Laboratory, Neuroscience Center, Departments of Neurology and Radiology (K.A., A.T.S., L.-D.D.P., E.H.L.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Neurology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence (M.K., K.L.F.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown (O.W.); Antioxidant Research Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging (J.B.B.) and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University, Boston, MA; and Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.K.F.)
| | - Loc-Duyen D Pham
- From the J. Philip Kistler Stroke Research Center, Department of Neurology (S.L., N.S.R., F.O.L., M.B.M., R.E.G., T.K.T., A.J.D.), Department of Radiology (H.L., G.J.H.), and Neuroprotection Research Laboratory, Neuroscience Center, Departments of Neurology and Radiology (K.A., A.T.S., L.-D.D.P., E.H.L.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Neurology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence (M.K., K.L.F.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown (O.W.); Antioxidant Research Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging (J.B.B.) and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University, Boston, MA; and Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.K.F.)
| | - Ona Wu
- From the J. Philip Kistler Stroke Research Center, Department of Neurology (S.L., N.S.R., F.O.L., M.B.M., R.E.G., T.K.T., A.J.D.), Department of Radiology (H.L., G.J.H.), and Neuroprotection Research Laboratory, Neuroscience Center, Departments of Neurology and Radiology (K.A., A.T.S., L.-D.D.P., E.H.L.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Neurology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence (M.K., K.L.F.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown (O.W.); Antioxidant Research Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging (J.B.B.) and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University, Boston, MA; and Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.K.F.)
| | - Gordon J Harris
- From the J. Philip Kistler Stroke Research Center, Department of Neurology (S.L., N.S.R., F.O.L., M.B.M., R.E.G., T.K.T., A.J.D.), Department of Radiology (H.L., G.J.H.), and Neuroprotection Research Laboratory, Neuroscience Center, Departments of Neurology and Radiology (K.A., A.T.S., L.-D.D.P., E.H.L.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Neurology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence (M.K., K.L.F.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown (O.W.); Antioxidant Research Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging (J.B.B.) and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University, Boston, MA; and Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.K.F.)
| | - Eng H Lo
- From the J. Philip Kistler Stroke Research Center, Department of Neurology (S.L., N.S.R., F.O.L., M.B.M., R.E.G., T.K.T., A.J.D.), Department of Radiology (H.L., G.J.H.), and Neuroprotection Research Laboratory, Neuroscience Center, Departments of Neurology and Radiology (K.A., A.T.S., L.-D.D.P., E.H.L.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Neurology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence (M.K., K.L.F.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown (O.W.); Antioxidant Research Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging (J.B.B.) and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University, Boston, MA; and Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.K.F.)
| | - Jeffrey B Blumberg
- From the J. Philip Kistler Stroke Research Center, Department of Neurology (S.L., N.S.R., F.O.L., M.B.M., R.E.G., T.K.T., A.J.D.), Department of Radiology (H.L., G.J.H.), and Neuroprotection Research Laboratory, Neuroscience Center, Departments of Neurology and Radiology (K.A., A.T.S., L.-D.D.P., E.H.L.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Neurology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence (M.K., K.L.F.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown (O.W.); Antioxidant Research Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging (J.B.B.) and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University, Boston, MA; and Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.K.F.)
| | - Paul E Milbury
- From the J. Philip Kistler Stroke Research Center, Department of Neurology (S.L., N.S.R., F.O.L., M.B.M., R.E.G., T.K.T., A.J.D.), Department of Radiology (H.L., G.J.H.), and Neuroprotection Research Laboratory, Neuroscience Center, Departments of Neurology and Radiology (K.A., A.T.S., L.-D.D.P., E.H.L.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Neurology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence (M.K., K.L.F.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown (O.W.); Antioxidant Research Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging (J.B.B.) and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University, Boston, MA; and Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.K.F.)
| | - Steven K Feske
- From the J. Philip Kistler Stroke Research Center, Department of Neurology (S.L., N.S.R., F.O.L., M.B.M., R.E.G., T.K.T., A.J.D.), Department of Radiology (H.L., G.J.H.), and Neuroprotection Research Laboratory, Neuroscience Center, Departments of Neurology and Radiology (K.A., A.T.S., L.-D.D.P., E.H.L.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Neurology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence (M.K., K.L.F.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown (O.W.); Antioxidant Research Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging (J.B.B.) and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University, Boston, MA; and Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.K.F.)
| | - Karen L Furie
- From the J. Philip Kistler Stroke Research Center, Department of Neurology (S.L., N.S.R., F.O.L., M.B.M., R.E.G., T.K.T., A.J.D.), Department of Radiology (H.L., G.J.H.), and Neuroprotection Research Laboratory, Neuroscience Center, Departments of Neurology and Radiology (K.A., A.T.S., L.-D.D.P., E.H.L.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Neurology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence (M.K., K.L.F.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown (O.W.); Antioxidant Research Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging (J.B.B.) and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy (P.E.M.), Tufts University, Boston, MA; and Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.K.F.)
| |
Collapse
|
28
|
Insight into the contribution of isoprostanoids to the health effects of omega 3 PUFAs. Prostaglandins Other Lipid Mediat 2017; 133:111-122. [DOI: 10.1016/j.prostaglandins.2017.05.005] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2017] [Revised: 04/07/2017] [Accepted: 05/31/2017] [Indexed: 12/30/2022]
|
29
|
Shoeibi A, Razmi N, Ghabeli Juibary A, Hashemy SI. The Evaluation and Comparison of Oxidative Stress in Hemorrhagic and Ischemic Stroke. CASPIAN JOURNAL OF NEUROLOGICAL SCIENCES 2017. [DOI: 10.29252/nirp.cjns.3.11.206] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
|
30
|
Galano JM, Lee YY, Oger C, Vigor C, Vercauteren J, Durand T, Giera M, Lee JCY. Isoprostanes, neuroprostanes and phytoprostanes: An overview of 25years of research in chemistry and biology. Prog Lipid Res 2017; 68:83-108. [PMID: 28923590 DOI: 10.1016/j.plipres.2017.09.004] [Citation(s) in RCA: 114] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2017] [Revised: 09/14/2017] [Accepted: 09/14/2017] [Indexed: 02/07/2023]
Abstract
Since the beginning of the 1990's diverse types of metabolites originating from polyunsaturated fatty acids, formed under autooxidative conditions were discovered. Known as prostaglandin isomers (or isoprostanoids) originating from arachidonic acid, neuroprostanes from docosahexaenoic acid, and phytoprostanes from α-linolenic acid proved to be prevalent in biology. The syntheses of these compounds by organic chemists and the development of sophisticated mass spectrometry methods has boosted our understanding of the isoprostanoid biology. In recent years, it has become accepted that these molecules not only serve as markers of oxidative damage but also exhibit a wide range of bioactivities. In addition, isoprostanoids have emerged as indicators of oxidative stress in humans and their environment. This review explores in detail the isoprostanoid chemistry and biology that has been achieved in the past three decades.
Collapse
Affiliation(s)
- Jean-Marie Galano
- Institut des Biomolécules Max Mousseron, UMR 5247 CNRS, ENSCM, Université de Montpellier, France
| | - Yiu Yiu Lee
- School of Biological Sciences, The University of Hong Kong, Hong Kong Special Administrative Region
| | - Camille Oger
- Institut des Biomolécules Max Mousseron, UMR 5247 CNRS, ENSCM, Université de Montpellier, France
| | - Claire Vigor
- Institut des Biomolécules Max Mousseron, UMR 5247 CNRS, ENSCM, Université de Montpellier, France
| | - Joseph Vercauteren
- Institut des Biomolécules Max Mousseron, UMR 5247 CNRS, ENSCM, Université de Montpellier, France
| | - Thierry Durand
- Institut des Biomolécules Max Mousseron, UMR 5247 CNRS, ENSCM, Université de Montpellier, France
| | - Martin Giera
- Leiden University Medical Center, Center for Proteomics and Metabolomics, Albinusdreef 2, 2300RC Leiden, The Netherlands
| | - Jetty Chung-Yung Lee
- School of Biological Sciences, The University of Hong Kong, Hong Kong Special Administrative Region.
| |
Collapse
|
31
|
Ng GJ, Quek AM, Cheung C, Arumugam TV, Seet RC. Stroke biomarkers in clinical practice: A critical appraisal. Neurochem Int 2017; 107:11-22. [DOI: 10.1016/j.neuint.2017.01.005] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2016] [Revised: 01/05/2017] [Accepted: 01/08/2017] [Indexed: 02/04/2023]
|
32
|
van 't Erve TJ, Kadiiska MB, London SJ, Mason RP. Classifying oxidative stress by F 2-isoprostane levels across human diseases: A meta-analysis. Redox Biol 2017; 12:582-599. [PMID: 28391180 PMCID: PMC5384299 DOI: 10.1016/j.redox.2017.03.024] [Citation(s) in RCA: 116] [Impact Index Per Article: 16.6] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2017] [Revised: 03/23/2017] [Accepted: 03/24/2017] [Indexed: 02/07/2023] Open
Abstract
The notion that oxidative stress plays a role in virtually every human disease and environmental exposure has become ingrained in everyday knowledge. However, mounting evidence regarding the lack of specificity of biomarkers traditionally used as indicators of oxidative stress in human disease and exposures now necessitates re-evaluation. To prioritize these re-evaluations, published literature was comprehensively analyzed in a meta-analysis to quantitatively classify the levels of systemic oxidative damage across human disease and in response to environmental exposures. In this meta-analysis, the F2-isoprostane, 8-iso-PGF2α, was specifically chosen as the representative marker of oxidative damage. To combine published values across measurement methods and specimens, the standardized mean differences (Hedges’ g) in 8-iso-PGF2α levels between affected and control populations were calculated. The meta-analysis resulted in a classification of oxidative damage levels as measured by 8-iso-PGF2α across 50 human health outcomes and exposures from 242 distinct publications. Relatively small increases in 8-iso-PGF2α levels (g<0.8) were found in the following conditions: hypertension (g=0.4), metabolic syndrome (g=0.5), asthma (g=0.4), and tobacco smoking (g=0.7). In contrast, large increases in 8-iso-PGF2α levels were observed in pathologies of the kidney, e.g., chronic renal insufficiency (g=1.9), obstructive sleep apnoea (g=1.1), and pre-eclampsia (g=1.1), as well as respiratory tract disorders, e.g., cystic fibrosis (g=2.3). In conclusion, we have established a quantitative classification for the level of 8-iso-PGF2α generation in different human pathologies and exposures based on a comprehensive meta-analysis of published data. This analysis provides knowledge on the true involvement of oxidative damage across human health outcomes as well as utilizes past research to prioritize those conditions requiring further scrutiny on the mechanisms of biomarker generation. Oxidative damage is highly variable in human conditions as measured by F2-isoprostanes. Respiratory tract and urogenital diseases have the highest F2-isoprostanes. Cancer and cardiovascular diseases have surprisingly low F2-isoprostanes.
Collapse
Affiliation(s)
- Thomas J van 't Erve
- Immunity, Inflammation and Disease Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, 27709 NC, USA.
| | - Maria B Kadiiska
- Immunity, Inflammation and Disease Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, 27709 NC, USA
| | - Stephanie J London
- Immunity, Inflammation and Disease Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, 27709 NC, USA; Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, 27709 NC, USA
| | - Ronald P Mason
- Immunity, Inflammation and Disease Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, 27709 NC, USA
| |
Collapse
|
33
|
Roy J, Fauconnier J, Oger C, Farah C, Angebault-Prouteau C, Thireau J, Bideaux P, Scheuermann V, Bultel-Poncé V, Demion M, Galano JM, Durand T, Lee JCY, Le Guennec JY. Non-enzymatic oxidized metabolite of DHA, 4(RS)-4-F 4t-neuroprostane protects the heart against reperfusion injury. Free Radic Biol Med 2017; 102:229-239. [PMID: 27932075 DOI: 10.1016/j.freeradbiomed.2016.12.005] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/07/2016] [Revised: 11/28/2016] [Accepted: 12/04/2016] [Indexed: 10/20/2022]
Abstract
Acute myocardial infarction leads to an increase in oxidative stress and lipid peroxidation. 4(RS)-4-F4t-Neuroprostane (4-F4t-NeuroP) is a mediator produced by non-enzymatic free radical peroxidation of the cardioprotective polyunsaturated fatty acid, docosahexaenoic acid (DHA). In this study, we investigated whether intra-cardiac delivery of 4-F4t-NeuroP (0.03mg/kg) prior to occlusion (ischemia) prevents and protects rat myocardium from reperfusion damages. Using a rat model of ischemic-reperfusion (I/R), we showed that intra-cardiac infusion of 4-F4t-NeuroP significantly decreased infarct size following reperfusion (-27%) and also reduced ventricular arrhythmia score considerably during reperfusion (-41%). Most notably, 4-F4t-NeuroP decreased ventricular tachycardia and post-reperfusion lengthening of QT interval. The evaluation of the mitochondrial homeostasis indicates a limitation of mitochondrial swelling in response to Ca2+ by decreasing the mitochondrial permeability transition pore opening and increasing mitochondria membrane potential. On the other hand, mitochondrial respiration measured by oxygraphy, and mitochondrial ROS production measured with MitoSox red® were unchanged. We found decreased cytochrome c release and caspase 3 activity, indicating that 4-F4t-NeuroP prevented reperfusion damages and reduced apoptosis. In conclusion, 4-F4t-NeuroP derived from DHA was able to protect I/R cardiac injuries by regulating the mitochondrial homeostasis.
Collapse
Affiliation(s)
- Jérôme Roy
- Inserm U1046 - UMR CNRS 9214 PHYMEDEX, Université de Montpellier, Montpellier, France.
| | - Jérémy Fauconnier
- Inserm U1046 - UMR CNRS 9214 PHYMEDEX, Université de Montpellier, Montpellier, France
| | - Camille Oger
- IBMM, CNRS UMR 5247, Université de Montpellier, ENSCM, Montpellier, France
| | - Charlotte Farah
- Inserm U1046 - UMR CNRS 9214 PHYMEDEX, Université de Montpellier, Montpellier, France
| | | | - Jérôme Thireau
- Inserm U1046 - UMR CNRS 9214 PHYMEDEX, Université de Montpellier, Montpellier, France
| | - Patrice Bideaux
- Inserm U1046 - UMR CNRS 9214 PHYMEDEX, Université de Montpellier, Montpellier, France
| | - Valérie Scheuermann
- Inserm U1046 - UMR CNRS 9214 PHYMEDEX, Université de Montpellier, Montpellier, France
| | | | - Marie Demion
- Inserm U1046 - UMR CNRS 9214 PHYMEDEX, Université de Montpellier, Montpellier, France
| | - Jean-Marie Galano
- IBMM, CNRS UMR 5247, Université de Montpellier, ENSCM, Montpellier, France
| | - Thierry Durand
- IBMM, CNRS UMR 5247, Université de Montpellier, ENSCM, Montpellier, France
| | | | - Jean-Yves Le Guennec
- Inserm U1046 - UMR CNRS 9214 PHYMEDEX, Université de Montpellier, Montpellier, France
| |
Collapse
|
34
|
Ohlow MJ, Sohre S, Granold M, Schreckenberger M, Moosmann B. Why Have Clinical Trials of Antioxidants to Prevent Neurodegeneration Failed? - A Cellular Investigation of Novel Phenothiazine-Type Antioxidants Reveals Competing Objectives for Pharmaceutical Neuroprotection. Pharm Res 2016; 34:378-393. [DOI: 10.1007/s11095-016-2068-0] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2016] [Accepted: 11/11/2016] [Indexed: 12/16/2022]
|
35
|
The Arachidonate 15-Lipoxygenase Enzyme Product 15-HETE Is Present in Heart Tissue from Patients with Ischemic Heart Disease and Enhances Clot Formation. PLoS One 2016; 11:e0161629. [PMID: 27552229 PMCID: PMC4994938 DOI: 10.1371/journal.pone.0161629] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2016] [Accepted: 08/09/2016] [Indexed: 01/22/2023] Open
Abstract
Ischemic heart disease is a major cause of death and morbidity and the search for novel therapeutic targets is still required. We have previously shown that the enzyme arachidonate 15 lipoxygenase (ALOX15), which catalyzes the conversion of arachidonic acid to 15-hydroxy eicosatetraenoic acid (15-HETE), is highly expressed in ischemic heart tissue, but its role in the pathogenesis of ischemic heart disease is unclear. Here we showed that expression of ALOX15, but not ALOX12 or ALOX15B, was increased in ischemic versus non-ischemic human heart biopsy samples. A similar ALOX expression pattern was found in hypoxic human cardiomyocytes and cardiac endothelial cells. We also showed that levels of 15-HETE were significantly higher in ischemic versus non-ischemic human heart biopsy samples and showed a tendency to increase in serum from the patients with ischemic heart disease. Moreover, hypoxia increased the production of 15-HETE levels from human cardiomyocytes and cardiac endothelial cells. The hypoxia-induced increase in 15-HETE levels from human cardiomyocytes was inhibited by the ALOX15 inhibitor baicalein. Finally, by using intrinsic rotational thromboelastometry, we showed that human whole blood clotted faster in the presence of 15-HETE. In summary, we propose that increased ALOX15 expression in heart tissue under ischemic conditions may lead to increased production of 15-HETE, potentially contributing to thrombosis.
Collapse
|
36
|
Abidin MHZ, Abdullah N, Abidin NZ. Therapeutic properties ofPleurotusspecies (oyster mushrooms) for atherosclerosis: A review. INTERNATIONAL JOURNAL OF FOOD PROPERTIES 2016. [DOI: 10.1080/10942912.2016.1210162] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
37
|
The Role of Omega-3 Polyunsaturated Fatty Acids in Stroke. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 2016; 2016:6906712. [PMID: 27433289 PMCID: PMC4940554 DOI: 10.1155/2016/6906712] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/29/2016] [Revised: 05/16/2016] [Accepted: 05/26/2016] [Indexed: 12/15/2022]
Abstract
Stroke is the third commonest cause of death following cardiovascular diseases and cancer. In particular, in recent years, the morbidity and mortality of stroke keep remarkable growing. However, stroke still captures people attention far less than cardiovascular diseases and cancer. Past studies have shown that oxidative stress and inflammation play crucial roles in the progress of cerebral injury induced by stroke. Evidence is accumulating that the dietary supplementation of fish oil exhibits beneficial effects on several diseases, such as cardiovascular diseases, metabolic diseases, and cancer. Omega-3 polyunsaturated fatty acids (n-3 PUFAs), the major component of fish oil, have been found against oxidative stress and inflammation in cardiovascular diseases. And the potential of n-3 PUFAs in stroke treatment is attracting more and more attention. In this review, we will review the effects of n-3 PUFAs on stroke and mainly focus on the antioxidant and anti-inflammatory effects of n-3 PUFAs.
Collapse
|
38
|
Canavero I, Sherburne HA, Tremble SM, Clark WM, Cipolla MJ. Effects of Acute Stroke Serum on Non-Ischemic Cerebral and Mesenteric Vascular Function. Transl Stroke Res 2016; 7:156-65. [PMID: 26809954 DOI: 10.1007/s12975-016-0449-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2015] [Revised: 12/17/2015] [Accepted: 01/08/2016] [Indexed: 02/03/2023]
Abstract
We investigated the effects of circulating factors in serum obtained from patients in the acute phase of different subtypes of ischemic stroke on non-ischemic cerebral and mesenteric arteries, as a potential mechanism involved in influencing regional perfusion and thus clinical evolution. Posterior cerebral arteries (PCAs) and mesentery arteries (MAs) isolated from Wistar Kyoto rats were perfused with serum from acute stroke patients with large vessel disease without (LVD) or with hypertension (LVD + HTN), cardioembolism with hypertension (CE + HTN), or physiologic saline as controls. Myogenic activity and nitric oxide-dependent vasorelaxation were assessed after 2 h of intraluminal exposure to serum. Vascular function was differentially affected by sera. Exposure to LVD serum increased myogenic tone and produced endothelial dysfunction in both PCAs and MAs. However, CE + HTN serum increased tone and decreased smooth muscle sensitivity to NO in vessels from both vascular beds. LVD + HTN serum was associated with reduced smooth muscle sensitivity to NO in vessels from both vascular beds but increased tone only in PCAs. Inflammation and oxidative stress, determined by measurement of high sensitivity C-reactive protein, uric acid, and free 8-isoprostane, were enhanced in all the serum groups. These results demonstrate vasoactive properties of acute stroke serum related to stroke subtypes that could potentially contribute to the pathogenesis of early hemodynamic-based clinical events.
Collapse
Affiliation(s)
- Isabella Canavero
- Department of Neurological Sciences, University of Vermont College of Medicine, 149 Beaumont Ave., HSRF 416A, Burlington, VT, 05405, USA
| | - Helene A Sherburne
- Department of Neurological Sciences, University of Vermont College of Medicine, 149 Beaumont Ave., HSRF 416A, Burlington, VT, 05405, USA
| | - Sarah M Tremble
- Department of Neurological Sciences, University of Vermont College of Medicine, 149 Beaumont Ave., HSRF 416A, Burlington, VT, 05405, USA
| | - Wayne M Clark
- Department of Neurology, Oregon Stroke Center, Oregon Health and Science University, Portland, OR, USA
| | - Marilyn J Cipolla
- Department of Neurological Sciences, University of Vermont College of Medicine, 149 Beaumont Ave., HSRF 416A, Burlington, VT, 05405, USA. .,Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Vermont College of Medicine, Burlington, VT, USA. .,Department of Pharmacology, University of Vermont College of Medicine, Burlington, VT, USA.
| |
Collapse
|
39
|
Roy J, Oger C, Thireau J, Roussel J, Mercier-Touzet O, Faure D, Pinot E, Farah C, Taber DF, Cristol JP, Lee JCY, Lacampagne A, Galano JM, Durand T, Le Guennec JY. Nonenzymatic lipid mediators, neuroprostanes, exert the antiarrhythmic properties of docosahexaenoic acid. Free Radic Biol Med 2015; 86:269-78. [PMID: 25911196 DOI: 10.1016/j.freeradbiomed.2015.04.014] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/20/2015] [Revised: 03/18/2015] [Accepted: 04/11/2015] [Indexed: 12/21/2022]
Abstract
Neuroprostanes are lipid mediators produced by nonenzymatic free radical peroxidation of docosahexaenoic acid (DHA). DHA is associated with a lower atherosclerosis risk, suggesting a beneficial role in cardiovascular diseases. The aim of this study was to investigate the influence of DHA peroxidation on its potentially antiarrhythmic properties (AAP) in isolated ventricular cardiomyocytes and in vivo in post-myocardial infarcted mice. Calcium imaging and biochemical experiments indicate that cardiac arrhythmias induced by isoproterenol are associated with Ca(2+) leak from the sarcoplasmic reticulum after oxidation and phosphorylation of the type 2 ryanodine receptor (RyR2) leading to dissociation of the FKBP12.6/RyR2 complex. Both oxidized DHA and 4(RS)-4-F4t-NeuroP prevented cellular arrhythmias and posttranslational modifications of the RyR2 leading to a stabilized FKBP12.6/RyR2 complex. DHA per se did not have AAP. The AAP of 4(RS)-4-F4t-NeuroP was also observed in vivo. In this study, we challenged the paradigm that spontaneously formed oxygenated metabolites of lipids are undesirable as they are unconditionally toxic. This study reveals that the lipid mediator 4(RS)-4-F4t-neuroprostane derived from nonenzymatic peroxidation of docosahexaenoic acid can counteract such deleterious effects through cardiac antiarrhythmic properties. Our findings demonstrate 4(RS)-4-F4t-NeuroP as a mediator of the cardioprotective AAP of DHA. This discovery opens new perspectives for products of nonenzymatic oxidized ω3 polyunsaturated fatty acids as potent mediators in diseases that involve ryanodine complex destabilization such as ischemic events.
Collapse
Affiliation(s)
- Jérôme Roy
- INSERM U1046-UMR 9214, Centre National de la Recherche Scientifique, Physiologie et Médecine Expérimentale du Coeur et des Muscles, Université de Montpellier, 34295 Montpellier Cedex 5, France
| | - Camille Oger
- Institut des Biomolécules Max Mousseron, UMR 5247, Centre National de la Recherche Scientifique, Université de Montpellier, ENSCM, Montpellier, France
| | - Jérôme Thireau
- Institut des Biomolécules Max Mousseron, UMR 5247, Centre National de la Recherche Scientifique, Université de Montpellier, ENSCM, Montpellier, France
| | - Julien Roussel
- INSERM U1046-UMR 9214, Centre National de la Recherche Scientifique, Physiologie et Médecine Expérimentale du Coeur et des Muscles, Université de Montpellier, 34295 Montpellier Cedex 5, France
| | - Olivia Mercier-Touzet
- INSERM U1046-UMR 9214, Centre National de la Recherche Scientifique, Physiologie et Médecine Expérimentale du Coeur et des Muscles, Université de Montpellier, 34295 Montpellier Cedex 5, France
| | - Delinger Faure
- INSERM U1046-UMR 9214, Centre National de la Recherche Scientifique, Physiologie et Médecine Expérimentale du Coeur et des Muscles, Université de Montpellier, 34295 Montpellier Cedex 5, France; Institut des Biomolécules Max Mousseron, UMR 5247, Centre National de la Recherche Scientifique, Université de Montpellier, ENSCM, Montpellier, France
| | - Edith Pinot
- Institut des Biomolécules Max Mousseron, UMR 5247, Centre National de la Recherche Scientifique, Université de Montpellier, ENSCM, Montpellier, France
| | - Charlotte Farah
- INSERM U1046-UMR 9214, Centre National de la Recherche Scientifique, Physiologie et Médecine Expérimentale du Coeur et des Muscles, Université de Montpellier, 34295 Montpellier Cedex 5, France
| | - Douglass F Taber
- Department of Chemistry and Biochemistry, University of Delaware, Newark, DE 19716, USA
| | - Jean-Paul Cristol
- INSERM U1046-UMR 9214, Centre National de la Recherche Scientifique, Physiologie et Médecine Expérimentale du Coeur et des Muscles, Université de Montpellier, 34295 Montpellier Cedex 5, France
| | - Jetty C Y Lee
- School of Biological Sciences, The University of Hong Kong, Hong Kong, SAR
| | - Alain Lacampagne
- INSERM U1046-UMR 9214, Centre National de la Recherche Scientifique, Physiologie et Médecine Expérimentale du Coeur et des Muscles, Université de Montpellier, 34295 Montpellier Cedex 5, France
| | - Jean-Marie Galano
- Institut des Biomolécules Max Mousseron, UMR 5247, Centre National de la Recherche Scientifique, Université de Montpellier, ENSCM, Montpellier, France
| | - Thierry Durand
- Institut des Biomolécules Max Mousseron, UMR 5247, Centre National de la Recherche Scientifique, Université de Montpellier, ENSCM, Montpellier, France
| | - Jean-Yves Le Guennec
- INSERM U1046-UMR 9214, Centre National de la Recherche Scientifique, Physiologie et Médecine Expérimentale du Coeur et des Muscles, Université de Montpellier, 34295 Montpellier Cedex 5, France.
| |
Collapse
|
40
|
Kanďár R. The ratio of oxidized and reduced forms of selected antioxidants as a possible marker of oxidative stress in humans. Biomed Chromatogr 2015; 30:13-28. [PMID: 26053056 DOI: 10.1002/bmc.3529] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2014] [Revised: 05/20/2015] [Accepted: 05/29/2015] [Indexed: 02/04/2023]
Abstract
Oxidative stress is an imbalance between reactive oxygen species exposure and the ability of organisms to detoxify the reactive intermediates and to repair the oxidative damage of biologically important molecules. Many clinical studies of oxidative stress unfortunately provide conflicting and contradictory results. The ability of antioxidant systems to adequately respond to oxidative stress can be used in laboratory diagnostics. In the present review, methods using the ratio of reduced and oxidized forms of uric acid, ascorbic acid, glutathione and coenzyme Q10 as suitable indicators of oxidative stress are discussed. From the mentioned publications it is evident that suitable sample preparation prior to analysis is crucial.
Collapse
Affiliation(s)
- Roman Kanďár
- Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Pardubice, Czech Republic
| |
Collapse
|
41
|
Esiaba I, Angeles DM, Holden MS, Tan JBC, Asmerom Y, Gollin G, Boskovic DS. Urinary Allantoin Is Elevated in Severe Intraventricular Hemorrhage in the Preterm Newborn. Transl Stroke Res 2015; 7:97-102. [PMID: 25994284 DOI: 10.1007/s12975-015-0405-y] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2014] [Revised: 04/06/2015] [Accepted: 05/08/2015] [Indexed: 11/27/2022]
Abstract
Germinal matrix intraventricular hemorrhage (IVH) is the most common type of intracranial hemorrhage observed in preterm neonates. It is a precursor of poor neurocognitive development, cerebral palsy, and death. The pathophysiology is not well defined, but damage to the fragile germinal matrix vasculature may be due to free radicals generated during inflammation and as a consequence of ischemia followed by reperfusion. Assessment of the oxidative stress status in these infants is therefore important. Urinary allantoin concentration was measured in preterm neonates as a marker of oxidative stress associated with IVH. Urine was collected from 44 preterm neonates at four time points between 24 and 72 hours of life (HOL), and the allantoin content was determined by gas chromatography mass spectrometry (GCMS). Records were retrospectively reviewed, and the incidence and severity of IVH was categorized as follows: no IVH (n = 24), mild (grade 1-2) IVH (n = 13), and severe (grade 3-4) IVH (n = 7). Neonates with severe IVH showed significantly elevated allantoin levels vs subjects with no IVH from 36 HOL (0.098 ± 0.013 μmol and 0.043 ± 0.007 μmol, respectively, p = 0.002). The allantoin concentration remained elevated even at 72 HOL (0.079 ± 0.014 μmol and 0.033 ± 0.008 μmol, respectively, p = 0.021). There were no significant differences in allantoin levels in the no IVH and mild IVH groups. IVH was diagnosed by head imaging on average at about 11th postnatal day. Urinary allantoin levels were significantly elevated during the first 3 days of life in the neonates subsequently diagnosed with severe IVH, suggesting that oxidative stress might be a crucial factor in IVH pathogenesis. Further studies are needed to assess the usefulness of urinary allantoin in early identification of preterm infants at risk for or with severe IVH and monitoring of the response to interventions designed to prevent or treat it.
Collapse
Affiliation(s)
- Ijeoma Esiaba
- Department of Earth and Biological Sciences, School of Medicine, Loma Linda University, Loma Linda, CA, 92350, USA
| | - Danilyn M Angeles
- Department of Basic Sciences, School of Medicine, Loma Linda University, Loma Linda, CA, 92350, USA
| | - Megan S Holden
- Department of Basic Sciences, School of Medicine, Loma Linda University, Loma Linda, CA, 92350, USA.,Division of Biochemistry, School of Medicine, Loma Linda University, Loma Linda, CA, 92350, USA
| | - John B C Tan
- Department of Basic Sciences, School of Medicine, Loma Linda University, Loma Linda, CA, 92350, USA.,Division of Biochemistry, School of Medicine, Loma Linda University, Loma Linda, CA, 92350, USA
| | - Yayesh Asmerom
- Department of Basic Sciences, School of Medicine, Loma Linda University, Loma Linda, CA, 92350, USA
| | - Gerald Gollin
- Division of Pediatric Surgery, School of Medicine, Loma Linda University, Loma Linda, CA, 92350, USA
| | - Danilo S Boskovic
- Department of Earth and Biological Sciences, School of Medicine, Loma Linda University, Loma Linda, CA, 92350, USA. .,Department of Basic Sciences, School of Medicine, Loma Linda University, Loma Linda, CA, 92350, USA. .,Division of Biochemistry, School of Medicine, Loma Linda University, Loma Linda, CA, 92350, USA.
| |
Collapse
|
42
|
Kaandorp JJ, Benders MJNL, Schuit E, Rademaker CMA, Oudijk MA, Porath MM, Oetomo SB, Wouters MGAJ, van Elburg RM, Franssen MTM, Bos AF, de Haan TR, Boon J, de Boer IP, Rijnders RJP, Jacobs CJWFM, Scheepers LHCJ, Gavilanes DAW, Bloemenkamp KWM, Rijken M, van Meir CA, von Lindern JS, Huisjes AJM, Bakker SCMJER, Mol BWJ, Visser GHA, Van Bel F, Derks JB. Maternal allopurinol administration during suspected fetal hypoxia: a novel neuroprotective intervention? A multicentre randomised placebo controlled trial. Arch Dis Child Fetal Neonatal Ed 2015; 100:F216-23. [PMID: 25512466 DOI: 10.1136/archdischild-2014-306769] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/12/2014] [Accepted: 11/17/2014] [Indexed: 12/18/2022]
Abstract
OBJECTIVE To determine whether maternal allopurinol treatment during suspected fetal hypoxia would reduce the release of biomarkers associated with neonatal brain damage. DESIGN A randomised double-blind placebo controlled multicentre trial. PATIENTS We studied women in labour at term with clinical indices of fetal hypoxia, prompting immediate delivery. SETTING Delivery rooms of 11 Dutch hospitals. INTERVENTION When immediate delivery was foreseen based on suspected fetal hypoxia, women were allocated to receive allopurinol 500 mg intravenous (ALLO) or placebo intravenous (CONT). MAIN OUTCOME MEASURES Primary endpoint was the difference in cord S100ß, a tissue-specific biomarker for brain damage. RESULTS 222 women were randomised to receive allopurinol (ALLO, n=111) or placebo (CONT, n=111). Cord S100ß was not significantly different between the two groups: 44.5 pg/mL (IQR 20.2-71.4) in the ALLO group versus 54.9 pg/mL (IQR 26.8-94.7) in the CONT group (difference in median -7.69 (95% CI -24.9 to 9.52)). Post hoc subgroup analysis showed a potential treatment effect of allopurinol on the proportion of infants with a cord S100ß value above the 75th percentile in girls (ALLO n=5 (12%) vs CONT n=10 (31%); risk ratio (RR) 0.37 (95% CI 0.14 to 0.99)) but not in boys (ALLO n=18 (32%) vs CONT n=15 (25%); RR 1.4 (95% CI 0.84 to 2.3)). Also, cord neuroketal levels were significantly lower in girls treated with allopurinol as compared with placebo treated girls: 18.0 pg/mL (95% CI 12.1 to 26.9) in the ALLO group versus 32.2 pg/mL (95% CI 22.7 to 45.7) in the CONT group (geometric mean difference -16.4 (95% CI -24.6 to -1.64)). CONCLUSIONS Maternal treatment with allopurinol during fetal hypoxia did not significantly lower neuronal damage markers in cord blood. Post hoc analysis revealed a potential beneficial treatment effect in girls. TRIAL REGISTRATION NUMBER NCT00189007, Dutch Trial Register NTR1383.
Collapse
Affiliation(s)
- Joepe J Kaandorp
- Department of Perinatology, University Medical Center, Utrecht, The Netherlands
| | - Manon J N L Benders
- Department of Perinatology, University Medical Center, Utrecht, The Netherlands
| | - Ewoud Schuit
- Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands
| | - Carin M A Rademaker
- Department of Clinical Pharmacy, University Medical Center, Utrecht, The Netherlands
| | - Martijn A Oudijk
- Department of Perinatology, University Medical Center, Utrecht, The Netherlands
| | - Martina M Porath
- Department of Perinatology, Maxima Medical Center, Veldhoven, The Netherlands
| | | | | | - Ruurd M van Elburg
- Department of Perinatology, VU Medical Center, Amsterdam, The Netherlands Danone Research, Wageningen, The Netherlands
| | - Maureen T M Franssen
- Department of Perinatology, University Medical Center, Groningen, The Netherlands
| | - Arie F Bos
- Department of Perinatology, University Medical Center, Groningen, The Netherlands
| | - Timo R de Haan
- Department of Perinatology, Academic Medical Center, Amsterdam, The Netherlands
| | - Janine Boon
- Department of Perinatology, Diakonessenhuis, Utrecht, The Netherlands
| | - Inge P de Boer
- Department of Perinatology, Diakonessenhuis, Utrecht, The Netherlands
| | - Robbert J P Rijnders
- Department of Perinatology, Jeroen Bosch Medical Center, Den Bosch, The Netherlands
| | | | | | - Danilo A W Gavilanes
- Department of Perinatology, Maastricht University Medical Center, Maastricht, The Netherlands
| | - Kitty W M Bloemenkamp
- Department of Perinatology, Leids University Medical Center, Leiden, The Netherlands
| | - Monique Rijken
- Department of Perinatology, Leids University Medical Center, Leiden, The Netherlands
| | - Claudia A van Meir
- Department of Perinatology, Groene Hart Hospital, Gouda, The Netherlands
| | | | | | | | - Ben W J Mol
- Department of Perinatology, University Medical Center, Groningen, The Netherlands
| | - Gerard H A Visser
- Department of Perinatology, University Medical Center, Utrecht, The Netherlands
| | - Frank Van Bel
- Department of Perinatology, University Medical Center, Utrecht, The Netherlands
| | - Jan B Derks
- Department of Perinatology, University Medical Center, Utrecht, The Netherlands
| |
Collapse
|
43
|
Yen HC, Wei HJ, Lin CL. Unresolved issues in the analysis of F2-isoprostanes, F4-neuroprostanes, isofurans, neurofurans, and F2-dihomo-isoprostanes in body fluids and tissue using gas chromatography/negative-ion chemical-ionization mass spectrometry. Free Radic Res 2015; 49:861-80. [DOI: 10.3109/10715762.2015.1014812] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
44
|
Galano JM, Lee JCY, Gladine C, Comte B, Le Guennec JY, Oger C, Durand T. Non-enzymatic cyclic oxygenated metabolites of adrenic, docosahexaenoic, eicosapentaenoic and α-linolenic acids; bioactivities and potential use as biomarkers. Biochim Biophys Acta Mol Cell Biol Lipids 2014; 1851:446-55. [PMID: 25463478 DOI: 10.1016/j.bbalip.2014.11.004] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2014] [Revised: 10/07/2014] [Accepted: 11/07/2014] [Indexed: 02/04/2023]
Abstract
Cyclic oxygenated metabolites are formed in vivo through non-enzymatic free radical reaction of n-6 and n-3 polyunsaturated fatty acids (PUFAs) such as arachidonic (ARA C20:4 n-6), adrenic (AdA 22:4 n-6), α-linolenic (ALA 18:3 n-3), eicosapentaenoic (EPA 20:5 n-3) and docosahexaenoic (DHA 22:6 n-3) acids. These cyclic compounds are known as isoprostanes, neuroprostanes, dihomo-isoprostanes and phytoprostanes. Evidence has emerged for their use as biomarkers of oxidative stress and, more recently, the n-3PUFA-derived compounds have been shown to mediate bioactivities as secondary messengers. Accordingly, this review will focus on the cyclic oxygenated metabolites generated from AdA, ALA, EPA and DHA. This article is part of a Special Issue entitled "Oxygenated metabolism of PUFA: analysis and biological relevance".
Collapse
Affiliation(s)
- Jean-Marie Galano
- Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, CNRS, University Montpellier I and II, ENSCM, Faculty of Pharmacy, Montpellier, France
| | | | - Cecile Gladine
- INRA, UMR1019, UNH, CRNH Auvergne, Clermont-Ferrand, Clermont Université, Université d'Auvergne, Unité de Nutrition Humaine, Clermont-Ferrand, France
| | - Blandine Comte
- INRA, UMR1019, UNH, CRNH Auvergne, Clermont-Ferrand, Clermont Université, Université d'Auvergne, Unité de Nutrition Humaine, Clermont-Ferrand, France
| | - Jean-Yves Le Guennec
- INSERM U1046, Physiologie & Médecine Expérimentale du Cœur et des Muscles, University Montpellier I and II, Montpellier, France
| | - Camille Oger
- Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, CNRS, University Montpellier I and II, ENSCM, Faculty of Pharmacy, Montpellier, France
| | - Thierry Durand
- Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, CNRS, University Montpellier I and II, ENSCM, Faculty of Pharmacy, Montpellier, France
| |
Collapse
|
45
|
The isoprostanes--25 years later. Biochim Biophys Acta Mol Cell Biol Lipids 2014; 1851:433-45. [PMID: 25449649 DOI: 10.1016/j.bbalip.2014.10.007] [Citation(s) in RCA: 226] [Impact Index Per Article: 22.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2014] [Revised: 10/13/2014] [Accepted: 10/21/2014] [Indexed: 01/26/2023]
Abstract
Isoprostanes (IsoPs) are prostaglandin-like molecules generated independent of the cyclooxygenase (COX) by the free radical-induced peroxidation of arachidonic acid. The first isoprostane species discovered were isomeric to prostaglandin F2α and were thus termed F2-IsoPs. Since the initial discovery of the F2-IsoPs, IsoPs with differing ring structures have been identified as well as IsoPs from different polyunsaturated fatty acids, including eicosapentaenoic acid and docosahexanenoic acid. The discovery of these molecules in vivo in humans has been a major contribution to the field of lipid oxidation and free radical research over the course of the past 25 years. These molecules have been determined to be both biomarkers and mediators of oxidative stress in numerous disease settings. This review focuses on recent developments in the field with an emphasis on clinical research. Special focus is given to the use of IsoPs as biomarkers in obesity, ischemia-reperfusion injury, the central nervous system, cancer, and genetic disorders. Additionally, attention is paid to diet and lifestyle factors that can affect endogenous levels of IsoPs. This article is part of a Special Issue entitled "Oxygenated metabolism of PUFA: analysis and biological relevance."
Collapse
|
46
|
Li G, Millard SP, Peskind ER, Zhang J, Yu CE, Leverenz JB, Mayer C, Shofer JS, Raskind MA, Quinn JF, Galasko DR, Montine TJ. Cross-sectional and longitudinal relationships between cerebrospinal fluid biomarkers and cognitive function in people without cognitive impairment from across the adult life span. JAMA Neurol 2014; 71:742-51. [PMID: 24756381 DOI: 10.1001/jamaneurol.2014.445] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
IMPORTANCE Age-related cognitive decline among older individuals with normal cognition is a complex trait that potentially derives from processes of aging, inherited vulnerabilities, environmental factors, and common latent diseases that can progress to cause dementia, such as Alzheimer disease and vascular brain injury. OBJECTIVE To use cerebrospinal fluid (CSF) biomarkers to gain insight into this complex trait. DESIGN, SETTING, AND PARTICIPANTS Secondary analyses of an academic multicenter cross-sectional (n = 315) and longitudinal (n = 158) study of 5 neuropsychological tests (Immediate Recall, Delayed Recall, Trail Making Test Parts A and B, and Category Fluency) in cognitively normal individuals aged 21 to 100 years. MAIN OUTCOMES AND MEASURES To investigate the association of these cognitive function test results with age, sex, educational level, inheritance of the ε4 allele of the apolipoprotein E gene, and CSF concentrations of β-amyloid 42 (Aβ42) and tau (biomarkers of Alzheimer disease) as well as F2-isoprostanes (measures of free radical injury). RESULTS Age and educational level were broadly predictive of cross-sectional cognitive performance; of the genetic and CSF measures, only greater CSF F2-isoprostane concentration was significantly associated with poorer executive function (adjusted R2 ≤0.31). Longitudinal measures of cognitive abilities, except Category Fluency, also were associated broadly with age; of the genetic and CSF measures, only lower baseline CSF Aβ42 concentration was associated with longitudinal measures of immediate and delayed recall (marginal R2 ≤0.31). CONCLUSIONS AND RELEVANCE Our results suggest that age and educational level accounted for a substantial minority of variance in cross-sectional or longitudinal cognitive test performance in this large group of cognitively normal adults. Latent Alzheimer disease and other diseases that produce free radical injury, such as vascular brain injury, accounted for a small amount of variation in cognitive test performance across the adult human life span. Additional genetic and environmental factors likely contribute substantially to age-related cognitive decline.
Collapse
Affiliation(s)
- Ge Li
- School of Medicine, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle
| | - Steven P Millard
- Veterans Affairs (VA) Northwest Network Mental Illness Research, Education, and Clinical Center, VA Puget Sound Health Care System, Seattle, Washington
| | - Elaine R Peskind
- School of Medicine, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle2Veterans Affairs (VA) Northwest Network Mental Illness Research, Education, and Clinical Center, VA Puget Sound Health Care System, Seattle, Washington
| | - Jing Zhang
- Department of Pathology, School of Medicine, University of Washington, Seattle
| | - Chang-En Yu
- Department of Medicine, School of Medicine, University of Washington, Seattle5Geriatric Research, Education, and Clinical Center, VA Puget Sound Health Care System, Seattle, Washington
| | - James B Leverenz
- School of Medicine, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle6Department of Neurology, School of Medicine, University of Washington, Seattle
| | - Cynthia Mayer
- Veterans Affairs (VA) Northwest Network Mental Illness Research, Education, and Clinical Center, VA Puget Sound Health Care System, Seattle, Washington
| | - Jane S Shofer
- School of Medicine, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle
| | - Murray A Raskind
- School of Medicine, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle2Veterans Affairs (VA) Northwest Network Mental Illness Research, Education, and Clinical Center, VA Puget Sound Health Care System, Seattle, Washington
| | - Joseph F Quinn
- Department of Neurology, School of Medicine, Oregon Health and Science University, Portland8VA Parkinson's Disease Research, Education, and Clinical Centers, Portland, Oregon
| | - Douglas R Galasko
- School of Medicine, Department of Neurosciences, University of California, San Diego, La Jolla
| | - Thomas J Montine
- Department of Pathology, School of Medicine, University of Washington, Seattle
| |
Collapse
|
47
|
Kalogeris T, Bao Y, Korthuis RJ. Mitochondrial reactive oxygen species: a double edged sword in ischemia/reperfusion vs preconditioning. Redox Biol 2014; 2:702-14. [PMID: 24944913 PMCID: PMC4060303 DOI: 10.1016/j.redox.2014.05.006] [Citation(s) in RCA: 490] [Impact Index Per Article: 49.0] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2014] [Revised: 05/23/2014] [Accepted: 05/27/2014] [Indexed: 02/06/2023] Open
Abstract
Reductions in the blood supply produce considerable injury if the duration of ischemia is prolonged. Paradoxically, restoration of perfusion to ischemic organs can exacerbate tissue damage and extend the size of an evolving infarct. Being highly metabolic organs, the heart and brain are particularly vulnerable to the deleterious effects of ischemia/reperfusion (I/R). While the pathogenetic mechanisms contributing to I/R-induced tissue injury and infarction are multifactorial, the relative importance of each contributing factor remains unclear. However, an emerging body of evidence indicates that the generation of reactive oxygen species (ROS) by mitochondria plays a critical role in damaging cellular components and initiating cell death. In this review, we summarize our current understanding of the mechanisms whereby mitochondrial ROS generation occurs in I/R and contributes to myocardial infarction and stroke. In addition, mitochondrial ROS have been shown to participate in preconditioning by several pharmacologic agents that target potassium channels (e.g., ATP-sensitive potassium (mKATP) channels or large conductance, calcium-activated potassium (mBKCa) channels) to activate cell survival programs that render tissues and organs more resistant to the deleterious effects of I/R. Finally, we review novel therapeutic approaches that selectively target mROS production to reduce postischemic tissue injury, which may prove efficacious in limiting myocardial dysfunction and infarction and abrogating neurocognitive deficits and neuronal cell death in stroke.
Collapse
Affiliation(s)
- Theodore Kalogeris
- Department of Medical Pharmacology and Physiology, School of Medicine, Dalton Cardiovascular Research Center, University of Missouri, 1 Hospital Drive, Columbia, MO 65212-0001, United States of America
| | - Yimin Bao
- Department of Medical Pharmacology and Physiology, School of Medicine, Dalton Cardiovascular Research Center, University of Missouri, 1 Hospital Drive, Columbia, MO 65212-0001, United States of America
| | - Ronald J Korthuis
- Department of Medical Pharmacology and Physiology, School of Medicine, Dalton Cardiovascular Research Center, University of Missouri, 1 Hospital Drive, Columbia, MO 65212-0001, United States of America
| |
Collapse
|
48
|
Navarro-Yepes J, Zavala-Flores L, Anandhan A, Wang F, Skotak M, Chandra N, Li M, Pappa A, Martinez-Fong D, Del Razo LM, Quintanilla-Vega B, Franco R. Antioxidant gene therapy against neuronal cell death. Pharmacol Ther 2014; 142:206-30. [PMID: 24333264 PMCID: PMC3959583 DOI: 10.1016/j.pharmthera.2013.12.007] [Citation(s) in RCA: 83] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2013] [Accepted: 11/26/2013] [Indexed: 12/21/2022]
Abstract
Oxidative stress is a common hallmark of neuronal cell death associated with neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, as well as brain stroke/ischemia and traumatic brain injury. Increased accumulation of reactive species of both oxygen (ROS) and nitrogen (RNS) has been implicated in mitochondrial dysfunction, energy impairment, alterations in metal homeostasis and accumulation of aggregated proteins observed in neurodegenerative disorders, which lead to the activation/modulation of cell death mechanisms that include apoptotic, necrotic and autophagic pathways. Thus, the design of novel antioxidant strategies to selectively target oxidative stress and redox imbalance might represent important therapeutic approaches against neurological disorders. This work reviews the evidence demonstrating the ability of genetically encoded antioxidant systems to selectively counteract neuronal cell loss in neurodegenerative diseases and ischemic brain damage. Because gene therapy approaches to treat inherited and acquired disorders offer many unique advantages over conventional therapeutic approaches, we discussed basic research/clinical evidence and the potential of virus-mediated gene delivery techniques for antioxidant gene therapy.
Collapse
Affiliation(s)
- Juliana Navarro-Yepes
- Redox Biology Center, University of Nebraska-Lincoln, Lincoln, NE 68583, United States; School of Veterinary Medicine and Biomedical Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583, United States; Department of Toxicology, CINVESTAV-IPN, Mexico City, Mexico
| | - Laura Zavala-Flores
- Redox Biology Center, University of Nebraska-Lincoln, Lincoln, NE 68583, United States; School of Veterinary Medicine and Biomedical Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583, United States
| | - Annadurai Anandhan
- Redox Biology Center, University of Nebraska-Lincoln, Lincoln, NE 68583, United States; School of Veterinary Medicine and Biomedical Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583, United States
| | - Fang Wang
- Department of Mechanical and Materials Engineering, University of Nebraska-Lincoln, Lincoln, NE 68583, United States
| | - Maciej Skotak
- Department of Mechanical and Materials Engineering, University of Nebraska-Lincoln, Lincoln, NE 68583, United States
| | - Namas Chandra
- Department of Mechanical and Materials Engineering, University of Nebraska-Lincoln, Lincoln, NE 68583, United States
| | - Ming Li
- Department of Psychology, University of Nebraska-Lincoln, Lincoln, NE 68583, United States
| | - Aglaia Pappa
- Department of Molecular Biology and Genetics, Democritus University of Thrace, University Campus, Dragana, Alexandroupolis, Greece
| | - Daniel Martinez-Fong
- Department of Physiology, Biophysics and Neurosciences, CINVESTAV-IPN, Mexico City, Mexico
| | | | | | - Rodrigo Franco
- Redox Biology Center, University of Nebraska-Lincoln, Lincoln, NE 68583, United States; School of Veterinary Medicine and Biomedical Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583, United States.
| |
Collapse
|
49
|
Vijil C, Hermansson C, Jeppsson A, Bergström G, Hultén LM. Arachidonate 15-lipoxygenase enzyme products increase platelet aggregation and thrombin generation. PLoS One 2014; 9:e88546. [PMID: 24533104 PMCID: PMC3922896 DOI: 10.1371/journal.pone.0088546] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2013] [Accepted: 01/06/2014] [Indexed: 11/19/2022] Open
Abstract
Atherosclerotic cardiovascular diseases are the leading causes of morbidity and mortality worldwide. We have previously shown that arachidonate 15-lipoxygenase B (ALOX15B) is highly expressed in atherosclerotic carotid plaques, and elucidation of mechanisms downstream of activated lipoxygenases may be relevant to our understanding of the genesis of atherosclerotic diseases. We examined 120 carotid plaques from patients with symptomatic carotid artery stenosis and showed that the extent of ALOX15B staining was significantly increased in carotid plaques with thrombosis. Impedance aggregometry analyses showed that the ALOX15B enzyme products 15-HETE and 15-HPETE increased platelet aggregation. By using a calibrated automatic thrombin assay, we showed that the ALOX15B products also increased both peak levels of thrombin and the total endogenous thrombin potential. Moreover, platelet aggregation was increased by addition of cell lysates from ischemic human macrophages, whereas platelet aggregation was reduced after knockdown of ALOX15B in human macrophages. Our data show that ALOX15B expression in human carotid plaques is associated with thrombus formation and that enzyme products of ALOX15B increase platelet aggregation and thrombin generation. We therefore propose that activated ALOX15B in macrophages may play a role in the induction of atherothrombotic events by increasing platelet aggregation and thrombin generation.
Collapse
Affiliation(s)
- Carolina Vijil
- Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Cecilia Hermansson
- Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Anders Jeppsson
- Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Göran Bergström
- Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Lillemor Mattsson Hultén
- Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden
- Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- * E-mail:
| |
Collapse
|
50
|
Niki E. Biomarkers of lipid peroxidation in clinical material. Biochim Biophys Acta Gen Subj 2014; 1840:809-17. [DOI: 10.1016/j.bbagen.2013.03.020] [Citation(s) in RCA: 374] [Impact Index Per Article: 37.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2013] [Revised: 03/14/2013] [Accepted: 03/17/2013] [Indexed: 11/28/2022]
|